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I remember the day I came in the UK with the intent to live an experience at the University of Kent 
observing how to conduct sport researches.  
 
I’ve been completely fascinated by the facilities, the equipment, the technicians, the PhD students, the 
Master students, the lecturers and most important by the numerous volunteers that took part in those 
experiments… (brave people J). 
 
For me was a kind of playground, all I have read inside books was there, amazing!!! Since I came in 
Kent I though that it would have been a long and difficult ride due to cultural barriers that I faced from 
the first day I went at the University as “Visitors”.  
 
The “English” language I studied at High School was not the English language I faced at the 
University. Thanks God I was in a good companion of foreigner students and the communication was 
not such a difficult thing as with English people.  
 
While I was Visitors I used to work early in the morning of the week-end in a fast-food as kitchen 
closer and I remember my long conversations with vegetables when I did the washing-up. My daily 
questions were: “Shall I begin to understand English people talking? Shall I talk to people more 
fluently? Shall….Shall…Shall… After 3 weeks from my arrive in the Uk I decided, even encouraged 
by my girlfriend Suher A.K.A. “Bimbi”, to participate to English teaching classes in London… bad 
idea, there were more Italians and Spaniards than English people in London and I though to be destined 
to speak “English Maccaronico” until the ends of my days. 
 
Notably, my Spanish language became better and better during that time… 
 
I found in Walter and Luca my anchor points at that time, they’ve been living in Kent from 2 years 
and they were running research studies under Sam Marcora supervision.  
Prof. Sam Marcora was the reason why I decided to leave Italy, I was tremendously curios about the 
research conducted by Sam and the good speeches about his methodologies that in Italy was something 
of unusual… the typical “CERVELLO IN FUGA”. 
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From the first day I step at the University of Kent, Sam made my self welcome, I really thank you Sam 
for your hospitality even if we did not pass so a lot of time together due to his travels around the world. 
Every time I had a problem Sam suggested to ask to Walter. 
 
Therefore, I knew Walter A.K.A. Walteruzzo, Staianz. At the beginning he was submitting his PhD 
Thesis and was between England and Wales but after a while I came permanently in Kent. 
What a guy… Try to pick-up a country in Europe … ok, Walter probably has lived there at least 6 
months of his life, what a Super-trump guy. 
 
It was probably his energy, his will to be curious and the way he was helping people to solved their 
problem; “Walter do you remember Akhram and Ali ambushes for blocking you? Ahahahah”. I’ve 
moved my first steps in the academic world with him, yes because I forgot to say I had 9 months 
contract as research assistant in a project funded by the Ministry of Defense where Walter was ahead.  
 
Could you imagine that? 3 months ago I was cutting bread and making sandwiches and now I was a 
member of the staff at the University of Kent?!?...I should remind this more often when I’m feeling 
sad, depress and unhappy!!!! There’s always a chance, we have just to wait our moment and be 
prepared to start a new adventure. 
 
Yes, this was probably the best working experience of my time and I used to recount every single 
episode to Bimbi when we had dinner in that time. We basically spent 2 hours during the day together 
because she woke up very early in the morning (4.00 am) and I back home late in the night (21/22). 
Bimbi waited me terribly tired every single day for sharing dinner and talking about the day. I will 
never forget it, you are wonderful life companion, you are Mother Nature force, I LOVE YOU!! 
 
Life went well, work was good and I never felt the research we were working at as a real job. We used 
to work between 10 to 12 hours/day, our salvation was the coffee machine that Walter brought from 
Napoli, the authentic “caffettiera napoletana”. It was a kind of talisman for us, the brain-stimulation 
we needed when training session began at 7 am…what a training time-table. 
 
We had a special collaborator, Walter’s brother A.K.A. “Pinuccio Santamaria” helping us to deal busy 
moment of the day when there were all three cycle-ergometers occupied by the participants. Thank 
you Ale for helping us to deal it and thank you for preparing “pasta e patane”, “pasta e fasule” during 
that night we finished testing late in the night. 
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At that time I had not intention to begin a PhD career, I’m still thinking to be a “field-man” than a 
“desk-man”. I’m feeling peaceful to coach athletes, living on the pitch during the cold winters and the 
hot summers, but life not always goes as you planned. 
I felt football nostalgia, I grew up in football changing rooms with “any bloody Sunday” movie as the 
emblem of last 4 years in Italy. I felt empty, no more happy as I was before… Homesickness!!! 
 
When you leave your birthplace is never easy, for none. I remember the very first period I was in 
London I was a mix of feelings… I was happy, sad, euphoric, depressed, happy again. 
Fortunately, my girlfriend was always closer to me and I remember she said “It’s not easy to me 
neither, but we are together and together is less difficult”. It’s true I have been never alone, probably 
I could not survived 3 years alone without her, thank you again for you “Gypsy state of mind!!!”. 
She is a traveller, she does not care about where to go, I think she loves much more the journey than 
the destination…what a GIRL!!! 
 
 
When my contract was expiring I had no ideas about my future. Fortunately, here it comes another 
important person of my last 5-years, John Dickinson. A research project funded by WADA needed a 
research assistant and John gave me the chance to be the main investigator.  
 
At the beginning I was a bit scared by this responsibility because this time, contrary to the previous 
project, I was alone and I had a lot of stuff to do.  
Basically, I lived for one year in the gym of the University to assist the participants in those it would 
have been lately the first study of my PhD. 
 
During this time I was thinking that it would have been a great opportunity to keep going with this 
research topic because was anti-doping fight was closer to my moral principles and to the sport I would 
see.  
This probably was the biggest reason of may choice to jump in a new adventure called doctorate of 
research. 
 
Such as big word for a strength & conditioning coach, I am not sure I will never get used to hear my 
name closer to this title…… I talked to John about my idea to start this long path and he was at that 
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time really happy, I’m sure he will never forget that day when he said “Why not Michele?!”… yes, 
because from that day I choked his email box. 
 
 
I really have a really good working relationship with John, he was quite available during throughout 
my PhD especially because I run two of the three studies abroad. Whether this could seems a problem, 
in my opinion was a good experience that make me feel proud of my career progresses. He supported 
me especially during the draft of the papers and I learnt from him how to write a paper and the way to 
do research, I’m happy of his supervision and I’m thankful to him!!! 
 
I think that when you begin PhD you don’t realise exactly how challenging and frustrating it will 
become especially the attempt to publish a study extracted from your PhD thesis. I spent hours and 
hours during my spare time to work on my thesis and on my studies and after a while I found my self 
lost. I deleted and re-wrote many many times same documents until I’ve got the chance to get a paper 
published!!! This represents for me a great achievement and the right acknowledgment for the hard 
work made by me from the first day I began this adventure. 
 
I can’t forget the night of the week-end seated on a chair with my “English teacher Bimbi” in the 
attempt to write as best I could a scientific paper. I have indelible in my eyes Suher’s reaction to the 
comments made by John in manuscript because she did not understand what particular grammar rule 
had scientific papers.  
Don’t worry my love, you will have time during the writing of other papers to understand it….. LOL 
I won’t forget the innumerous files and grammar books attached in the emails by you (Suher), it helped 
me to understand a little bit more how to create a paper.  
I still remember your “mantra”: “TESI, ANTITESI, SINTESI”. I had bad dreams with this jingle as 
soundtrack. 
 
I have to thank you, again, for the motivation and your abnegation in keeping me into my mission, 
getting my bad days less bitter. I have to confess that when I was in difficult you have been my extra 
energy and I finish this also to show you that hard work pay off!!!! I think that one part of this thesis 
is your, truly, and I really hope that the future will give you the opportunity to prosecute your studies 
and maybe obtaining a doctorate of research in foreign literature!!!  
You are a GEEK, similar to Sheldon Cooper J. 
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In conclusion, I thank you one more time to have always put my PhD before everything, before 
Saturday Nights out, before week-ends out, before YOU! 
You are such an incredible person, a pure soul!!! 
 
I have to thanks Luca, A.K.A. “caghino” because his strictness and his professional way to work make 
me feel improved as researcher and more patient as a man…we lived 1 week together in Swiss for a 
data collection and I really risked to kill him!!! (I would have kicked your bottom many times for your 
negative way to see the life… COME ON MATE don’t be so sad). 
 
Thank you Irisz, Andrea Nicolò, Chiara and “Kurdish gang”, I miss you guys. 
 
A special thanks to Jose A.K.A. o “maestro”, the Brazilian more Italian than me, our friendship is 
something special. You taught me a lot of in physiology of exercise and training tips but the most 
important life-lesson you taught me is represented by your simplicity, a person with noble principles 
and a big heart. I wish you the best as cyclist coach because you deserve it. I miss you my friend and 
I miss Marylin too. 
 
I have to thanks all the University staff for helping me in booking accommodations and flights for the 
conferences I participated during this marvelous years. How could I forget the good time spent in pubs 
and discos with John, Walter, Lex, Mark and others… You are great guys!!! 
 
I want thank you Mum and thank you Dad for the big opportunity you gave me to have an education; 
I hope to be good as you are with my sons in the future. Thank you Daddy for supporting me financially 
at the end of the PhD because I finished all my savers in the attempt to pay PhD fees. 
 
Thank you Sergio, A.K.A. Gigio for visiting me during my permanence in Brixton and in Bromley, 
you only missed Verona but it has been better for your liver J, we had funny time together with Walter 
in London!!! … If I accomplished this result you will graduate soon as well, you are always been the 
smart one!! so hurry UP!!  
 
Last but not least a special thanks to ME. 
You did it Michele, you fought as you never did before, you wanted and you get it, this is the results 
of great efforts and determination because honestly this was out you’re your comfort zone.  
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How can we measure our strength and limits if we don’t go over what we perceive as easy? The answer 
















“Challenges are what make life interesting, and overcoming 
them is what makes life meaningful” 
         





The prevalence of asthma related condition in athletes is higher than the general population. The use 
of inhaled β2-agonists (IBA) by athletes with an asthma related condition is common, however some 
question whether the therapy has ergogenic action.  
The purpose of this thesis was to investigate the ergogenic action of short and long acting IBA on 
athletic performance. 
According to this, the aim of the first study (Chapter 4) was to investigate whether long-term (5 weeks) 
daily administration of LABAs (12 µg formoterol and 100 µg salmeterol) during a resistance 
programme aimed to increase strength and power performance. Thirty-eight recreational males and 
females took part in this program developed in order to increase daily the training load in order to 
simulate training habits. Although no changes in strength and body mass were observed, running sprint 
performance was significantly improved in formoterol and salmeterol groups. The outcomes coming 
from this study suggest a probable enhancement of β2-adrenoceptors in the systemic concentration 
following this practice able to speed-up physiological adaptation showed to occur during resistance 
training. 
 
The second study (Chapter 5) investigated the physiological and performance effects of short acting 
IBA on 35-mt sprint performed both in “fatigued” and “non-fatigued” state by football players. In this 
study football players completed 35 m sprints prior to and immediately following a progressive 
intermittent running shuttle test to exhaustion (Yo-Yo intermittent recovery test). Prior to the trial 
football players inhaled either a placebo of 1600 µg salbutamol. No sprint enhancement was observed 
in sprints performed before and after the Yo-Yo intermittent recovery test following IBA 
administration when compared against placebo.  
 x 
The third study (Chapter 6) investigated the potential effect of long-acting β2-agonists inhalation on 
“non-fatigued” and “fatigued” conditions and was able to show increased 12-s sprint power output 
(PLA = 831 ± 112 W vs. SAL 915 ± 135 W) after one-hour cycling time-trial designed to induce 
fatigue in the cyclists. These findings suggest athletes using 100 µg long-acting IBA who engage in 
prolonged endurance events may become more resistant to fatigue. 
 
In conclusion, it seems that high therapeutic doses of long-acting β2-agonists may lead to enhanced 
sprinting performance and offset the onset of fatigue. 
 Future investigations should focus on the use and dose of inhaled long-acting β2-agonists in and out 
competition by athletes with asthma related condition to ensure they are not likely to experience 



















TABLE OF CONTENTS  
 
 
Declaration                         i 
Acknowledgements                        ii - iv      
Abstract                         v - vii       
List of Figures                        xii - xiii                 
List of Tables                         xiv - xv 
Abbreviations                                   xvi - xx  
          
 
Chapter 1 – INTRODUCTION            1-8 
 
                   
Chapter 2 -LITERATURE REVIEW                                                               9-45 
 
2.1 Background                                                                                                     10-12  
 
2.2 Asthma and Exercise Induced Bronchoconstriction (EIB) 12-21 
 2.2.1 Pathophysiology of asthma and EIB            13-14 
 2.2.2 Diagnosis of asthma                                    14-15                   
 2.2.3 Assessment to support diagnosis of EIB                      15-19 
2.2.4 Asthma Treatment & Management            19-21 
 
2.3 Asthma, EIB and the elite athlete              21-22 
  
2.4 β2-adrenergic receptors                               23-25 
2.4.1 Short and Long acting β2-agonists action model          23-25 
 
2.5 β2-agonists and the WADA Prohibited List of Substances and Methods        26-30 
 
2.6 Potential ergogenic action of β2-agonists in athletes                 30-33 
2.6.1 SABA and endurance performance            30-31    
2.6.2 LABA and endurance performance 32 
2.6.3 Long-term SABAs and LABAs effect on endurance performance  32-33  
 
2.7 The effect of β2-agonists administration on body composition                   34-37 
2.7.1 Anabolic effect induced by SABAs administration                  34-35 
2.7.2 Anabolic effect induced by LABAs administration                          36 
2.7.3 Anabolic mechanism induced by SABAs and LABAs                     36-37 
 
2.8 Strength and Power performance induced by β2-agonists administration        37-38 
 
2.9 Sprint performance induced by IBAs                                   39-41 
 xii 
 2.9.1 Sprint performance induced by SABAs            39-40 
 2.9.2 Sprint performance induced by LABAs            40-41 
 
2.10 Overall Summary                       41-43 
 
2.11 AIM of the Thesis               43-44 
 
2.12 HYPHOTHESIS of the Thesis                                                                       44-45 
    
  
Chapter 3 – General Methods             46-52 
 
3.1 “Spirometry test”               47-49 
3.2 “Eucapnic Voluntary Hyperpnoea Challenge”           49-52 
3.3 “Peak Oxygen Consumption (VO2peak)”           52 
   
 
Chapter 4 – “Improved Sprint Performance With Inhaled Long-Acting  
β2-agonists Combined With Resistance Training”            53-68 
 
 
4.1 Background               54-56 
 
4.2 Methods                56-61 
4.2.1 Study Participants                   56 
4.2.2 Broncho-provocation Challenge         57 
4.2.3 Treatment Groups         57 
4.2.4 Assessments         57 
4.2.5 30 Meters Sprint         58 
4.2.6 Isokinetic Dynamometry         58 
4.2.7 Maximal One Repetition Bench Press and incline Leg Press          58 
4.2.8 Power – Counter Movement Vertical Jump (CMJ)         59 
4.2.9 Body Composition         59 
4.2.10 Recovery, Sleep and Mood Questionnaires         59 
4.2.11 Strength and Power Training Program         60 
4.2.12 Statistical Analysis         60-61 
 
4.3 Results         62-65 
4.3.1 Baseline Groups Comparison         62 
4.3.2 30 Meters Sprint                   62 
4.3.3 Strength and Power Assessments         63 
4.3.4 Anthropometric measures         64 
4.3.5 Recovery, Sleep and Mood Questionnaires         64 
 xiii 
4.4 Discussion  65-67 
4.4.1 Limitations  67 




Chapter 5 – “The Effect of 1600 µg Inhaled Salbutamol Administration  
On 30-Meters Sprint Performance Pre and Post Yo-Yo Intermittent  
Running Challenge In Football Players” 69-84 
                                  
 
5.1 Background               70 
 
5.2 Methods                71-75 
5.2.1 Study participants             71 
5.2.2 Experimental protocol             72 
5.2.3 Sprint test              73 
5.2.4 Yo-Yo test (Yo-Yo IRT)            74 
5.2.5 Motivation and Mood questionnaires           74-75 
5.2.6 Statistical Analysis             75 
 
5.3 Results                76-80 
5.3.1 Participants characteristics            76 
5.3.2 30 m Sprint Pre and Post Yo-Yo IRT           76-78 
5.3.3 Yo-Yo Intermittent Recovery Test           79 
5.3.4 Mood and Motivation questionnaire           80 
 
5.4 Discussion                81-84 




CHAPTER 6 – “Acute Administration of Salmeterol Improves Sprint  
Performance Following Variable Cycling Trial”          85-99 
 
6.1 Background                          86-87        
 
6.2 Methods                            87-91                   
 6.2.1 Study participants                         87 
 6.2.2 Experimental protocol              87-88 
 6.2.3 Broncho-provocation Challenge            88 
 6.2.4 VO2Max Test                   88 
 xiv 
 6.2.5 Sprint Familiarisation                  88   
6.2.6 “Non-fatigued” Sprint test            88-89 
 6.2.7 Variable Cycling Trial                        89  
6.2.8 “Fatigued” Sprint test                        89-90 
6.2.9 Motivation Questionnaire                       90 
6.2.10 Statistical Analysis                        90-91 
 
6.3 Results                              91-94 
6.3.1 Participants Characteristics            91 
6.3.2 Motivation Questionnaire            91 
6.3.3 Sprint Power Analysis             91-92 
6.3.4 Sprint RMS Analysis                        92-93 
6.3.5 Variable Cycling Trial Perceptual and Physiological Analysis        93-94 
 
6.4 Discussion                95-98 
6.4.1 Technical Consideration and Study Limitations         99 
6.4.2 Conclusion              99 
 
 
Chapter 7 – General Discussion         100-116 
 
 
References                           118 - 139 
 
Appendices                140 - 152 
 
Ethical approvals                                 141 - 148 












LIST OF FIGURES 
 
CHAPTER 2 - LITERATURE REVIEW 
Figure 2.1       “ANATOMY OF AIRWAY DURING ASTHMA SYMTOMS”                   pag 12 
              
 
CHAPTER 3 - General Methods 
Figure 3.1       “MAXIMAL FLOW-VOLUME LOOP ACCEPTANCE CRITERIA”             pag 49                               
Figure 3.2       “EQUIPMENT USED TO PERFORM EVH TEST”                                    pag 51  
 
 
CHAPTER 4 – “Improved Sprint Performance With Inhaled Long-Acting  
    β2-agonists Combined With Resistance Training” 
 
Figure 4.1       “30 METERS SPRINT IN SAL, FOR AND PLA”                                      pag 62 
 
 
CHAPTER 5 – “The Effect of 1600 µg Inhaled Salbutamol Administration  
                            on 30-Meters Sprint Performance Pre and Post Yo-Yo  
                Intermittent Running Challenge In Football Players” 
       
Figure 5.1A    “Best Sprint: at pre and post Yo-Yo IRT in SAL and PLA”            pag 77 
Figure 5.1B    “Mean Sprint: at pre and post Yo-Yo IRT in SAL and PLA”          pag 77  
Figure 5.1C    “Maximal Speed at pre and post Yo-Yo IRT in SAL and PLA”      pag 78                                 
Figure 5.2       “Lactate values collected after sprint pre Yo-Yo IRT and after  
             sprint post Yo-Yo IRT in SAL and PLA”                                       pag 78 
Figure 5.3       “Distance covered by SAL and PLA during the Yo-Yo IRT”         pag 79 
Figure 5.4A   “Heart rate response at the end of each Yo-Yo IRT level completed  
                       by the participants”                                                                           pag 79 
Figure 5.4B   “RPE response at the end of each Yo-Yo IRT level completed by  




CHAPTER 6 – “Acute Administration of Salmeterol Improves Sprint  
    Performance Following Variable Cycling Trial” 
 
Figure 6.1   “Effect of treatment on Peak Power Output (A) and  
   Mean Power Output (B)”                                                               pag  92       
Figure 6.2   “Effect of treatment on physiological and psychological responses  
                     during Variable Cycling Trial                                                             pag  93 
Figure 6.3   “Effect of salmeterol on blood lactate after 12-s sprint  
























LIST OF TABLES 
 
CHAPTER 2 - LITERATURE REVIEW 
 
Table 2.1 “DIRECT AND INDIRECT STIMULI "                                                          pag 19  
Table 2.2 “ASTHMA THERAPIES”                                                                            pag 20-21 
Table 2.3 “PREVALENCE OF EIB IN ELITE BRITISH ATHLETES”                               pag 22 
Table 2.4 “THE HISTORY OF THE β2-AGONISTS AND THEIR GUIDELINES  
       FOR USE IN THE ATHLETIC POPULATION”                                             pag 28-30 
    
CHAPTER 4 – “Improved Sprint Performance With Inhaled Long-Acting  
    β2-agonists Combined With Resistance Training” 
 
Table 4.1 “30 METERS SPRINT, POWER & STRENGTH PERFORMANCE  
       IN SAL, FOR & PLA”                                                                                pag 63  
Table 4.2 “SKINFOLDS & BODY MASS in SAL, FOR AND PLA”                                 pag 64  
Table 4.3 “REST Q RECOVERY & STRESS INDEX IN SAL, FOR AND PLA”                 pag 65 
 
                
CHAPTER 5 – “The Effect of 1600 µg Inhaled Salbutamol Administration  
                            on 30-Meters Sprint Performance Pre and Post Yo-Yo  
                Intermittent Running Challenge In Football Players” 
 
Table 5.1 “Descriptive features of participants (n=13)”                                          pag 72 
Table 5.2 “Vigour at pre and post-test and Motivation at pre- test in  








AB     Abdominal 
ANOVA    Analysis of variance  
ARTP                Association for Respiratory Technology and Physiology  
ASL     Airway surface liquid 
AAF      Adverse analytical finding  
AC     Adenylate cyclase  
AHR     Airway hyper-responsiveness  
ATP     Adenosine tri-phosphat 
ATS     American Thoracic Society 
B     B-lymphocyte 
BbB     Breath-by-breath 
BF     Breathing frequency  
BHT    Breath holding time 
BPD     Breathing pattern disorder 
BTS     British Thoracic Society 
°C    Celsius degree 
Ca2+    Calcium  
cAMP     Cyclic adenosine monophosphate 
cm    Centimetre 
CMJ    Counter movement jump  
CNS     Central nervous system 
CO2     Carbon dioxide 
COPD    Chronic obstructive pulmonary disease 
 xix 
DB     Dysfunctional breathing 
DEXA    dual-energy x-ray absorptiometry 
DoU     Declaration of use 
EFL    Expiratory flow limitation 
EIA     Exercise-induced asthma  
EIB     Exercise-induced bronchoconstriction  
EIIS     Exercise-induced inspiratory symptoms 
EMG     Electromyography  
EVH     Eucapnic voluntary hyperpnoea  
EVH+ve    Eucapnic voluntary hyperpnoea positive  
EVH-ve    Eucapnic voluntary hyperpnoea negative 
ERS     European Respiratory Society 
FeNO     Fraction of exhaled nitric oxide 
FET     Forced expiratory time 
FEV1     Forced expiratory volume in one second  
FEV1/FVC    FEV1: FVC ratio  
FI    Fatigue Index 
FOR    Formoterol 
FVC     Forced vital capacity 
GB     Great British 
Gi      G-protein i  
GPCRs    G-protein coupled receptors 
HR     Heart rate  
HR peak    Peak heart rate 
HR max    Maximum heart rate 
 xx 
HVS     Hyperventilation syndrome 
ICS      Inhaled corticosteroid  
IgE      Immunoglobulin E  
IOC      International Olympic Committee  
IOC-MC   InternationalOlympicCommittee –Medical Commission 
IT    Italy 
kg    Kilogram 
Km      Kilometres  
L/min    Litre per minute 
La     Lactate 
LABA    Long acting beta agonist 
LT     leukotriene 
m    Metre 
Mc      mast Cell  
mg     milligrams  
ml     millilitres  
MLCK                myosin light-chain kinase  
mm     millimetres 
M      macrophage  
min    Minutes 
mg/l    Milligram per litre 
MIP     Maximal inspiratory pressure 
MEP               Maximal expiratory pressure 
ml/min                          Millilitres per minute 
ml/kg/min   Millilitres per kilogram of body weight per minute 
 xxi 
mmol/L   Millimoles per litre 
MPO    Mean Power Output 
MVV     Maximal voluntary ventilation  
n    Nano    
N     Number 
NA     Noradrenaline  
N2     Nitrogen  
O2     Oxygen  
p    Significance level 
PAP     Peak aerobic power  
PEF     Peak expiratory flow  
PKA     Protein kinase A 
PLA    Placebo 
PPO    Peak power output 
r    Reliability coefficient 
RER     Respiratory exchange ratio 
RIP     Repetitions 
RM     Repetition maximum 
RMS    Root mean Square 
RPE     Perceived exertion 
RPEL    Leg perceived exertion 
RPM     Revolutions per minute 
RSA    Repeated Sprint Ability 
RyR     Ryanodine receptor 
s    Seconds 
 xxii 
SABA    Short acting beta agonist 
SAL    Salmeterol 
SBM      Subepithelial basement membrane    
SD     Standard deviation  
SE      Standard error  
SEM     Mean standard error 
sEMG    Surface Electromyography 
SPSS    Statistical package for social sciences 
SR      Sarcoplasmic reticulum 
T     T-lymphoycte 
TT    Time trial 
TTE    Time to exhaustion 
TUE     Therapeutic use exemption 
TER                                        Terbutaline 
UK     United Kingdom 
USA    United States of America 
V̇E     Minute ventilation  
V̇CO2     Carbon dioxide production  
V̇O2     Oxygen consumption 
V̇O2 peak   Peak oxygen consumption 
vs.    Versus 
VT    Tidal volume  
W     Watts 
WADA     World Anti-Doping Agency 
WR     Work rate 
 xxiii 
YO-YO IRT   Yo-Yo intermittent recovery test 
yr    Year (s) 
β                                     Beta 
β2    Beta-2 
β2R     β2-Receptor 
e    Degrees of freedom 
μ      Micro  
μg     Micrograms 
μl     Microlitre 
μm    Micrometre 
=    Equal 
































Asthma is an obstructive airway disease that is characterised by a reversible 
bronchoconstriction driven by lower airway inflammation. The airway inflammation and 
bronchoconstriction related to asthma is only activated in the presence of a trigger (e.g. dust, 
pollen pollution). Exercise is a trigger for up to 90% of individuals with asthma (Mc Fadden & 
Gilbert, 1994). When exercise is the only trigger the condition is termed exercise-induced 
bronchoconstriction (EIB) (Mc Fadden & Gilbert, 1994). 
The prevalence of EIB among elite athletes is relatively high and can range between 10–70% 
(Levai et al., 2016; Dickinson et al., 2005). The prevalence is EIB between sports is variable 
and is largely dependent on the environment in which the sport is performed, the ventilatory 
demands of the sport and the method used to record the diagnosis (Weiler et al., 2010). 
Typically sports with the highest prevalence of EIB are endurance-based sports that require 
athletes to sustain a high minute ventilation that take place in challenging environments 
responsible of air-way dehydration. This temporary modification in the airways brings to water 
lost from the airway surface that terminates with bronchial smooth muscle contraction and 
consequence EIB. 
In most cases asthma and EIB can be managed appropriately using inhaled therapy in the form 
of corticosteroids and β2-agonists. The aim of the therapy is to prevent the occurrence of 
asthma/EIB and reduce the severity. Inhaled corticosteroid therapy is seen as the therapy to 
prevent the development of airway inflammation and bronchoconstriction, whereas β2-agonists 
provide immediate relief from bronchoconstriction by relaxing the constricted airway smooth 
muscle almost instantly following inhalation. Despite guidance to suggest athlete therapy 
should include both inhaled corticosteroid and β2-agonists therapy there is evidence of an 





Once an athlete with asthma/EIB is adequately managed they should be able to train and 
compete without compromising their airway health and at no disadvantage to non-asthmatic 
athletes. To the extent that athletes with documented asthma/EIB tend to out-perform non-
asthmatic athletes at the Olympic Games (Fitch, 2012). However, these findings have led some 
to suggest the therapy used by athletes with asthma/EIB provides them with an ergogenic 
advantage. A possible ergogenic effect provoked by these drugs, shown by increased glycolytic 
and glycogenolysis activity and a faster ATP resynthesis, has become a research topic since 
Torino 2006 Olympic Winter Games approved for IBA where 131 out of 193 athletes were 
recorded without previous asthma history (Fitch, 2006). 14.4% of them won a medal. Two years 
later, during Summer Olympic Games in Beijing (2008) this percentage became even larger 
with a fifth of the swimmers and cyclists (19.3% and 17.3%) were asthmatic; however, of these 
one out of three (32.9 % and 28.9%) was a medal winner. 
Instinctively, the potential ergogenic effect produced by IBAs administration could be 
presumable as supported by the data presented above; however, results collected in literature 
seem not to support this theory especially when aerobic performance is evaluated (Pluim et al., 
2011). 
In 2001, the International Olympic Committee (IOC) established the necessity for athletes to 
present verification of current asthma, exercise induced asthma (EIA), exercise induced 
bronchospasm (EIB) or airway hyper-responsiveness (AHR) through the Therapeutic Use 
Exception (TUE) certificate process. More specifically, to be granted a TUE the user must prove 
that the drug is necessary to treat an acute or chronic symptom, the drug is not going to produce 
any performance benefit and there is no permitted therapeutic alternative to the use of the 
prohibited drug.  
Therefore, the requirement of demonstrable evidence through the TUE process improves the 




annually) declares all β2-agonists are prohibited in and out competition except inhaled 
salbutamol, salmeterol and formoterol. Oral administration of any β2-agonists is banned. 
Salbutamol represents the most used short acting IBA (SABA) used by asthmatic people. As 
suggested by WADA (2019), therapeutic dose of inhaled salbutamol ranges from 200-400 µg, 
athletes are permitted to inhale up to 800 µg in any 12 hours period and 1600 µg in a 24-hour 
period (WADA Prohibited List, 2019). 
 
Studies present in literature seem not to show an ergogenic effect provoked by inhaled 
salbutamol administration (Pluim et al., 2011). More specifically, when endurance performance 
was investigated in therapeutic dose (Molphy et al., 2018; Goubault et al., 2001; Sporer et al., 
2008; Sandsund et al., 1998; Norris et al., 1996; Elers et al., 2010) no ergogenic effect was 
noted. Similar results have been observed after supra-therapeutic regime (Stewart et al., 2002; 
Dickinson et al., 2014; Koch et al., 2015a, 2015b; McKenzie et al., 1983; Goubault et al., 2001; 
Sporer et al., 2008). A study by Elers et al. (2012a) suggests that inhaling an extremely supra-
therapeutic salbutamol dose of 4000 μg results in no improvement in cycling time to exhaustion 
or oxygen kinetics.  This effect has been observed also at lower doses of salbutamol (800 μg) 
that was able to reduce time to exhaustion performance (Carlsen et al., 1997). Notably, despite 
no mechanisms were able to explain the results obtained by Carlsen (1997) a possible 
mechanism could be the premature fatigue experienced under salbutamol condition expressed 
by higher muscle perturbation compared to placebo condition. 
In contrast, after 800 µg salbutamol inhalation improved cycling time-trial performance was 
recorded by Van Baak et al., (2004). Notably, this change in performance was not explained 
by any measures taken such as β2-agonists concentration in plasma, glycerol and potassium 
levels or ventilatory levels collected at rest and after exercise. Moreover, the big inter-




by changes in subject fitness level. Similarly, work by Kalsen et al., (2013) has highlighted 
performance improvement following combined short (1600 μg salbutamol) and long-acting β2-
agonists inhalation (200 μg salmeterol; 36 μg formoterol). In addition to this, the amount of 
drug inhaled was maximal in both short and long-acting β2-agonists with ergogenic effects 
possibly explained by the high systemic level of drug reached after these doses. 
Contrasting evidence has been shown from studies that looked at the impact of high-doses of 
inhaled short acting β2-agonists on sprint and power performance 
No changes in performance were observed after therapeutic and supra-therapeutic salbutamol 
inhalation (Stewart et al., 2002; Norris et al., 1996; Morton et al., 1993; Meeuwisse et al., 1992). 
Conversely, some studies reported improvements in peak power anaerobic performance after 
low albuterol 180 µg dose (Signorile et al., 1992), after supra-therapeutic 800 µg dose (Decorte 
et al., 2013) and 1600 µg dose (Kalsen et al., 2013;).   
 
Mechanisms potentially responsible for improved performance following inhalation of short 
and/or long acting β2-agonists could be attributed to higher systemic concentration reached after 
supra-therapeutic dose regime (e.g. > 400 µg inhaled salbutamol). In detail, skeletal muscle 
hypertrophy has been associated to increased power production during sprint exercise (Kalsen 
et al., 2013) with slow-twitch fibers presenting shorter half-relaxation time after β2-agonists 
administration (Crivelli et al., 2011). The variation in half-relaxation time could be attributed 
to an increased rate of Ca2+ release and re-uptake within the skeletal muscles that has been 
indicated to increase force by an increase in intracellular Ca2+ transient amplitude (Cairns & 
Dulhunty, 1994). This effect may be produced by increased ryanodine receptor channel release 
of Ca2+ and sarcoplasmic reticulum Ca2+-ATPase reuptake of Ca2+ (Ha et al., 1999). 
Another mechanism observed after β2-agonists administration is the increased activity of the 




preventing loss of membrane excitability and development of fatigue (Sejersted & Sjøgaard, 
2000). Studies adopting oral salbutamol administration found amplified glycogenolysis and 
glycolysis in skeletal muscles, which is also supported by elevated venous lactate (Van Baak et 
al., 2004; Collomp et al., 2005). We could speculate that supra-therapeutic dose of β2-agonists 
could mimic the effect brought by different route of administration considered as an AAF (Elers 
et al., 2012).  
 
Other IBAs such as terbutaline have been largely investigated since the early 80’, it possesses 
analogous pharmacological actions to salbutamol in 2-4 mg recommended dosage (Sweetman, 
2011). The ergogenic effect showed by supra-therapeutic inhaled terbutaline administration has 
been recognised in sprint (Hostrup et al., 2014) and endurance performance (Kalsen et al., 
2014), but due to the difficulty in distinguishing between oral and inhaled administration this 
substance is presently on the list of prohibited substances redacted by WADA (2019) and 
banned for use by athletes. Athletes requesting to use terbutaline, via a TUE, can only be 
approved as long as no other permitted β2-agonists could represent an alternative therapeutic 
cure with a special treatment for those athletes used to inhaled terbutaline for a long time that 
kept this practice unchanged. 
 
Asthmatic athletes are responsible for the administration of medications and must follow the 
Anti-Doping rules as laid out by the World-Anti-Doping-Agency. They can be tested at any 
time of day on any day of the year during competitions as well during training and are obliged 
to communicate to authorities their domicile to be always available to test. Despite severe 
penalties (e.g. disqualified from competition for two years), recent sport history reports a few 
cases of athletes tested positive to β2-agonists drug. Former Italian cyclist Alessandro Petacchi, 




1320 ng.ml-1 in urine. He was disqualified for one year from all competitions. In 2014, Diego 
Ulissi reported almost double the urine cut-off limits (1900 ng.ml-1) and stopped from 
professional cycling season for 9 months with the accusation of negligence. Four Tour de 
France Winner Chris Froome, during 2017 “la Vuelta” was 19% over the decision limit (1040 
ng/ml) in urine sample collected. He was not suspended from competition due to the nature of 
the substance for which he was under investigation and because salbutamol was not considered 
a “specified substance” (WADA, 2017). 
The investigation on the British cyclist continued for several months until he was judged not 
guilty based on scientific paper results that showed a very large range of salbutamol 
concentrations, with a significant portion of virtual subjects (15.4%) exceeding the WADA 
threshold limit of 1000 ng ml-1 at 1 h post-dose (Heuberger et al., 2018). In addition, loss of 
body mass experienced by endurance athletes during long-stage (up to 5% of bodyweight) can 
lead to individuals presenting a urinary salbutamol concentration above 1200 ng.ml-1 (Haase 
et al., 2016); thus, dehydration can cover an important role in anti-doping analysis and 
significantly affect the concentration of salbutamol in urine samples.  
 
Most of the studies investigating inhaled β2-agonists have primarily focused on acute 
administration of therapeutic and supra-therapeutic dose. According to this, Dickinson et al., 
(2014) after 6 weeks daily inhaled administration of supra-therapeutic salbutamol dosage (1600 
µg) did not result in significant improvements in endurance, strength and power performances. 
However, due to difference in pharmacokinetic profile long-term daily administration of long-





The current World Anti-Doping Agency (2020) list of prohibited substances and methods 
permits athletes to use inhaled therapeutic doses of formoterol (54 µg per day) and salmeterol 
























































Breathing signifies both the start and the end of our lives, and it is the most fundamental of 
physiological process. This process of respiratory ventilation occurs automatically but it is 
possible to come under partial conscious control (e.g. during times of stress).  
 
At rest, the average adults takes 10 to 15 breaths per minute, with a tidal volume of 
approximately 0.5 L, producing a minute ventilation (VE) between 5 to 7.5 L.min-1 (Leonard et 
al., 2004).  VE depends on body size and metabolic rate (Gillooly et al., 2001). During high-
intensity exercise the rate and depth of breathing are increased, which requires the breathing 
muscles to contract more forcefully and quickly in order to raise tidal volume and expiratory 
airflow rate. Breathing frequency during high intensity exercise rises to around 40 to 50 breaths 
per minute; in a physically active young male, tidal volume rises approximately 3 to 4 L 
(minute ventilation is 120 to 160 L.min-1; Dempsey, 2019). Failure to do so, results in changes 
that lead to breathless, increased perception of effort, earlier on set of fatigue and earlier end 
point of exercise (when completing time trial to exhaustion or ramped incremental exercise 
efforts). At all intensities of exercise, the majority of the work of breathing is undertaken by 
the inspiratory muscles; expiration is always assisted to some extend by elastic energy that is 
stored in the expanded lungs and rib cage from the preceding inhalation. 
 
In susceptible individuals, it is possible that exercise can trigger bronchoconstriction. This is 
brought about by a switch mouth breathing and increased VE during exercise exposing the lower 
airways to “unconditioned” relatively dry, cold and unfiltered air. The action of the lower 




epithelial cells, which leads to water movement from airway cells to restore osmolarity balance 
to airway epithelial cells. This leads to cell shrinkage of airway inflammatory cells, release of 
airway inflammatory mediators and airway smooth contraction (Andersoon & Kippelen, 
2008). The bronchoconstriction typically occurs following a bout of continuous exercise 
peaking five to ten minutes post exercise. The above process is known as exercise induced 
bronchoconstriction (EIB) and is either reversible either spontaneously or through the use of 
asthma therapy such as inhaled β2-agonists (e.g. salbutamol).  
 
Asthma related conditions, such as EIB, may limit an athletes ability to appropriately ventilate 
their airways and therefore develop a respiratory limitation to exercise performance (Dempsey 
et al., 2008).  However, when athletes appropriately use asthma inhaler therapy to protect 
against asthma and EIB, they experience an improvement in airway health, reduction in 
asthma/EIB severity. Therefore, appropriate inhaler therapy enables athletes to perform on a 
level playing field with their non-asthmatic counter parts (Jackson et al., 2018).  
 
Well controlled Asthma/EIB should not be seen as a limitation to athletic performance, in fact, 
Fitch (2012) reported that athletes with asthma who compete at Olympic Games out-perform 
their non-asthmatic counterparts and are more successful at winning Olympic medals. This 
report is good news for athletes with asthma who should feel they can protect their airway 
health whilst competing on a level playing field against non-asthmatic athletes.  However, 
reports such as those by Fitch (2012), have led to some questioning whether the therapy athletes 
use to attenuate asthma/EIB has an ergogenic action providing athletes with asthma an 
advantage over their non-asthmatic counterparts. 
In this literature review I will cover the action of how asthma and EIB develops and how 




therapy has the potential to provide an ergogenic action. I will discuss the World Anti-Doping 
Agency (WADA) List of Prohibited Substances (WADA, 2020) and debate whether the code 
allows athletes with asthma to compete, protecting their airway health, and prevents 
unscrupulous athletes abusing asthma therapy for performance gain.   
 
2.2 Asthma and Exercise Induced Bronchoconstriction (EIB) 
 
Asthma is a reversible obstructive airway disease that, starting from normal airway status 
(FIGURE 2.1/B), is triggered when encounters a specific asthma trigger that leads to an 
inflammation process causing the bronchi to swell and airway smooth muscle to constrict 
creating airway resistance and reduction in expiratory airflow (FIGURE 2.1/C). The airway 
obstruction is reversible either spontaneously or through inhalation of bronchodilator therapy 
(e.g. inhaled β2-agonist). 
 














The severity of airway obstruction can differ between individual and only occurs in the 
presence of asthma triggers such as allergies, exposure to air pollution (cold and dries air), 
medications, emotional anxiety and stress (Reche et al., 2020). Many patients with asthma 
develop asthma symptoms when exercising, this is called exercise-induced 
bronchoconstriction (EIB). However, it possible that people only experience EIB in the absence 
of asthma, which is likely due to the elevated ventilatory volume of air inhaled and exhaled 
during their sport discipline (Molis & Molis, 2010).  
 
Asthma is one of the most prevalent respiratory diseases affecting more than 300 million people 
worldwide with a trend to increase the number of patients affected over the next 15–20 years 
(Masoli et al., 2004). EIB is an asthma related condition and it is estimated 80% - 90% of 
people with asthma experience EIB (Parsons & Mastronarde, 2005). The prevalence of EIB in 
athletic populations is greater than the prevalence of asthma in the UK general population (9-
12%; British Lung Foundation, asthma, Uk). The prevalence of asthma in the Great British 
Summer Olympic Team has been reported to be 21% (Dickinson et al., 2005) but the 
prevalence can range between sports with athletes in sports such as swimming (68%) being 
more susceptible to EIB than others (e.g. boxing 8%; Levai et al., 2016).  
 
 2.2.1 Pathophysiology of asthma and EIB 
 
The phenotypes of asthma and triggers (e.g. exercise, pollen, pollution) that initiate an 
inflammatory process differ between individuals (Froidure et al., 2016). However, once the 
trigger has activated the mechanism towards bronchoconstriction the process is similar in both 
asthma and EIB. Once the process has been triggered activation of mast cells, infiltration of 




initiated (Barnes, 2008). When these airway inflammatory cells (e.g. mast cells) are stimulated 
they release inflammatory mediators into the extra-cellular matrix including histamine, 
leukotriene (LT) D4 and prostaglandin (PG) D2 ending in a bronchoconstriction effect. 
 
In the case of individuals susceptible to EIB, sustained high minute ventilation during exercise 
leads to an increased exposure of the lower airway to relatively cold, dry air, which is required 
to be warmed and humidified by the lower airways. This results in dehydration of the airway 
surface liquid (ASL; Reinhard-Groebli & Nicod, 2017).  More specifically the airway 
dehydration leads to (1) an increase in intracellular osmolarity, (2) initial water movement from 
the surrounding cells toward the airway lumen, (3) the shrinkage of sub-epithelial cells and (4) 
the release of broncho-constrictive inflammatory mediators, including histamines, cytokines 
and leukotrienes; this causes a cascade of inflammatory process leading to airway smooth 
muscle constriction (Anderson & Kippelen, 2012; Hallstrand et al., 2013). 
 
2.2.2 Diagnosis of asthma 
 
Due to the various phenotypes of asthma there is not one gold standard test to diagnose the 
condition. Diagnosis of asthma is made by a combination of past history, physical examination 
and objective airway assessments (Quirt et al., 2018). 
The major feature of asthma is airway smooth muscle contraction, causing in obstructed 
airways during expiration phases and reduced forced expiratory volume in 1 second (FEV1) 
due to reduced flow rate through the airways. The most adopted test for lung function is 
spirometry (Dwyer, 2012), where measurements of FEV1, forced vital capacity (FVC) and their 
ratio (FEV1/FVC) are measured. If the FVC and the FEV1 are within 80% of predicted values, 




usually between 80-85%, with a ratio < 70% (and 65% in persons older than age 65) considered 
to be characteristic of obstructive airway disease (NICE, 2017). Individuals with an abnormal 
resting lung function a bronchodilation challenge is an appropriate assessment of airway 
reversibility. A bronchodilation challenge involves measurement of baseline spirometry, 
inhalation of 200 mcg salbutamol, then spirometry measured 15 minutes post inhalation. If 
FEV1 improved by 12% or more from baseline this was considered significant reversibility and 
used to support the diagnosis of asthma. Notably, when bronchoconstriction occurs there is a 
noticeable fall in FEV1, a greater time to FVC, and an FVC value that remains similar, bringing 
to an imbalance between FEV1/FVC from resting values (Hansen et al., 2007). 
 
2.2.3 Assessment to support diagnosis of EIB  
 
The American Thoracic Society states that EIB diagnosis is made based upon changes in lung 
function post-exercise and not based upon the presence of symptoms (Parsons et al., 2013). 
There are two recognised methods of challenge testing dependent upon whether the bronchial 
smooth muscle is elicited directly or indirectly (TABLE 2.1).  
 
Direct challenge tests such as methacholine are sensitive to detect asthma but are not entirely 
specific for EIB as subjects with other airway disorders may have direct AHR. However, a 
negative methacholine challenge test in a currently symptomatic patient is highly suggestive 
of an alternative diagnosis (Coates et al., 2017). 
Indirect airway challenges are the most appropriate to use and support a diagnosis of EIB. 
Indirect airway challenges are considered to be more appropriate as they indirectly trigger 
airway smooth muscle contraction by initiating the inflammatory pathways described above. 




Indirect airway challenge includes laboratory-based exercise challenges, sport-specific 
exercise challenge, eucapnic voluntary hyperpnoea (EVH) and dry powder mannitol.  
 
Direct airway challenges, because of the high sensitivity, work best to exclude asthma; a 
positive test result is consistent with but not diagnostic of asthma related conditions. On the 
contrary, indirect challenges are more specific for asthma but are insensitive, particularly for 
mild and/or well-controlled asthma. The lower sensitivity may relate to the fact that many 
indirect challenges (e.g. exercise, eucapnic voluntary hyperpnea, adenosine monophosphate) 
are dose limited (e.g. the dose of stimulus cannot be increased above a level based on 
physiology or solubility; Cockroft et al., 2009). In support of this, indirect challenges would be 




The exercise challenge involves a participant completing continuous exercise lasting between 
8-10 minutes in total.  The exercise should incorporate progressive increases in exercise 
intensity over about 2 to 4 minutes to achieve a high level of ventilation (for athletes V̇E must 
be > 25 times the FEV1), which then sustain for a further 4 to 6 minutes. The target HR during 
the final 4 to 6 minutes of the exercise should be > 80% HRmax for non-trained individuals 
and >90% HR max for trained individuals (Eggleston et al., 1979).  Measurements of FEV1 are 
made prior to exercise and then in duplicate at 3, 5, 7 10, 15 minutes post exercise, and the 
higher of the two values is recorded at each time point. The criterion to diagnose EIB using 






Due to the release of bronchodilation agents in the body (e.g. lysophosphatidic acid, 
phospholipase A2 and leukotriene C4), exercise that starts with a very low workload or uses a 
continuous increase in intensity for assessing maximum capacity may lead to false negative 
results (Anderson, 2011). Although a sports-specific exercise field test may simulate the 
exercise environment and demonstrate a reduction in airflow, due to its poor sensitivity for 
diagnosis and difficulty to perform reliably, this method of assessment may not be appropriate 
as the initial investigation for EIB (Dryden et al., 2010). 
Thus, conducting field based exercises challenge requires to monitoring the environmental 
conditions (e.g. temperature, humidity) and having appropriate  equipment to assess lung 
function (e.g. spirometer, heart rate monitor). In contrast, a laboratory-based exercise challenge 
is limited due to the controlled environment and less sport specific exercise. Therefore, the use 
of both forms exercise challenge may not be as sensitive to detect EIB in athletes. Hence, 
surrogate indirect airway challenges maybe more appropriate to assist in the diagnosis of EIB. 
 
Eucapnic Voluntary Hyperpnoea Challenges 
Eucapnic voluntary hyperpnoea (EVH) challenge is a surrogate for exercise. The EVH 
challenge requires a participant to sustain a high minute ventilation (85% of maximum 
voluntary ventilation) for six minutes inhaling a relatively dry (2% relative humidity) gas 
containing 21% O2, 5% CO2 and 74% nitrogen (N2). After the test lung function measurements 
are made at the same time interval as for exercise and a sustained ≥ 10% fall in FEV1 is 
considered a positive test (Anderson et al., 2001).  
 
EVH is more sensitive to detect the EIB compared with exercise. This is thought to be due to 




assessment (Rundell et al., 2004; Dickinson et al., 2005) and methocholine (Holzer et al., 
2003).   
 
Mannitol 
Dry powder mannitol inhalation increases the osmolarity of the airway surface and causes 
release of the same inflammatory mediators (Anderson & Kippelen, 2012). Mannitol has 
similar sensitivity to EVH when performed in summer athletes but poor sensitivity in detecting 
EIB in winter athletes (Holzer et al., 2003). The commercially available test kit contains pre-
packed capsules containing 5, 10, 20 or 40 mg of mannitol and an inhaler device. FEV1 is 
measured in duplicate 60 seconds after each 40 mg dose. A 15% fall in FEV1 at ≤ 635 mg is 
considered a positive test result (Anderson & Kippelen, 2012). 
 
Hyper-responsiveness to mannitol has been shown to have high specificity for a clinical 
diagnosis of asthma (95%), with a sensitivity of approximately 60% (Sverrild et al., 2009; 
2010). This sensitivity increases to 89% when the use of inhaled corticosteroids (ICS) is taken 
into account (Brannan et al., 2005). This finding means that like exercise, a positive mannitol 
test is consistent with the diagnosis of asthma, but a negative test does not exclude asthma 
(Anderson & Kippelen, 2012). 
 
In summary, an accurate diagnosis of asthma, should include a full symptoms history, physical 
examination and objective measurements of lung function (e.g. spirometry). The objective 
evidence of lung function should include evidence of airway reversibility if baseline lung 
function appears abnormal or evidence of bronchoconstriction following either a direct or 





       TABLE 2.1: DIRECT AND INDIRECT STIMULI 
Direct Stimuli Cholinergic agonist (methacoline, etc) 
Histamine 
Indirect Stimuli Exercise 
Anisotonic spray (mannitol, distilled water) 
Eucapnic Voluntary Hyperventilation (EVH) 
 
 
2.2.4 Asthma Treatment & Management  
  
While there is no cure for asthma, symptoms can be controlled with effective asthma therapy 
and management. A number of therapeutic strategies have been adopted in an attempt to control 
the symptoms associated with asthma, including β2-agonists, inhaled corticosteroids (ICS), and 
other anti-inflammatory agents (TABLE 2.2). 
 
The degree of airway hyperresponsiveness is aided by the administration of corticosteroids to 
reduce airway inflammation and the β2-agonists allow for airway smooth muscle relaxation, 
therefore bronchodilator therapies and inhaled corticosteroids are the preferred first choice of 
therapy for symptom relief in asthmatic individuals (McFadden & Gilbert ,1994). Among the 
β2-agonists, the individual agents vary in the rapidity of onset and duration of action. Inhaled, 
short-acting, selective β2-adrenergic agonists are the mainstay of acute asthma therapy, while 
long-acting, selective β2-adrenergic agonists play a role in long-term control of moderate to 







TABLE 2.2: ASTHMA THERAPIES  
Therapy Example of drug Mode of Action 
 
β2-Agonists (Short & 
Long-Acting) 
 
Salbutamol     Salmeterol 
Terbutaline     Formoterol 




• Increase levels of cAMP to 
relax bronchial smooth 
muscle through the inhibition 
of myosin light chain kinase. 
• Relaxation of smooth muscles 
•  Increase voluntary muscle 
strength & peak twitch force 
•  Increase lean mass 
•  Increase rates of glycolysis 
•  Increase rates of 
glycogenolysis 










• Reduction of prostaglandin 
synthesis (COX-2 inhibition) 
• Interference with synthesis of 
interleukin 1 and 2. 
• Inhibition of the synthesis of 
other cytokines. 





Monteluekast • Inhibit antigen-induced 









rupatadine, mepolizumab  
• Prevents the release of the 
mediators of type I allergic 
reactions, such histamine, from 






• Prevent the hydrolysis of 
cAMP, leading to 
bronchodilation and reduced 
inflammation 
• Inhibition of cell trafficking 
 
 
2.3 Asthma, EIB and the elite athlete  
 
Elite athletes are more likely to have asthma related conditions, such as EIB, than the general 
population. It has been reported in that 21% of the 2004 Great British Summer Olympic Team 
had an asthma related condition (Dickinson et al., 2005) which is more than double the  
prevalence of asthma in the UK general population (9%; Asthma UK).  
 
Athletes engaged in endurance-based sports are more susceptible to asthma related conditions 
such as EIB because they sustain relatively high VE over a prolonged period of training with 
significant volume of air entering the lower airways. Therefore, elite athletes who take part in 
certain sports such as swimming, cross-country skiing and rowing are more likely to experience 
EIB compare to other disciplines due to multiple physiological aspects such as a increment of 
ventilatory demand during physical activity and environmental conditions (TABLE 2.3; 




swimmers have asthma, and that this problem occurs due to extensive exposure to chlorine that 
swimmers experience.  
 
The inhalation of b2-agonists targets b2-adrenergic receptors present in the body stimulating 
the sympathetic nervous system (SNS) and increasing momentarily heart rate, energy 
mobilisation and skeletal muscle blood flow in order to get the body ready for physical 
performance.  
 













2.4 β2-adrenergic receptors 
 
In the airways of individuals experiencing smooth muscle contraction, activation of β2-
adrenergic receptors leads to relaxation of airway smooth muscle, dilation and opening of the 
airways. In particular, the combination of decreased intracellular calcium and protein kinase 
A, provoked by cyclic adenosine monophosphate (cAMP), activates myosin light-chain 
phosphatase that in addition with to calcium and potassium channel exert smooth muscle 
bronchodilation (Johnson, 2006). This is why inhaled b2-agonists therapy plays a significant 
role in the management of asthma and EIB for most individuals.  
 
In addition to the bronchodilation action, b2-agonists therapy may be used in a clinical setting 
to promote skeletal muscle hypertrophy (Westfall, 2006). The effect brought by b2-agonists 
administration has been identified with therapeutic applications for muscle wasting conditions 
such as sarcopenia, cancer cachexia, denervation and neuromuscular disease with the intent to 
reduce muscle weakness and enhance muscle growth (Lynch & Ryall, 2008). Despite the clear 
therapeutic application for b2-agonists use by athletes with asthma related conditions, there is 
a clear potential for asthma therapy to have an ergogenic action that may tempt unscrupulous 
athletes to seek the use of b2-agonists to better sport performance. 
 
2.4.1 Short and Long acting b2-agonists action model  
 
There are three types of b2-agonists: short-acting (SABA), long-acting (LABA) and ultra-long-
acting (ULABA). The principal difference in the clinical pharmacology of SABA, LABA and 
ULABA is represented by the duration of action on airway smooth muscle (SABA ~ 4 hours, 





The β2-agonists are similar in structure to adrenaline with a single benzene ring and an amino 
group side-chain. The LABAs such as formoterol and salmeterol have an additional benzene 
ring attached to the amino-group, which likely accounts for their longer duration of action 
(Anderson et al., 1994). The physicochemical nature of the interactions of formoterol or 
salmeterol with the membrane lipid bilayer that may determine the duration of action of these 
molecules; moreover, the side-chain affects the lipophilicity of salmeterol that is more lipid 
soluble than the moderately lipophilic formoterol molecule (Jeppsson et al., 1989). 
 
An important feature possessed only by LABAs is the capacity to assert relaxation of airway 
smooth muscle; this retention of salmeterol in the tissue is very persistent even after 10 wash-
out cycles or numerous hours of continuous superfusion of the tissue with drug-free medium 
(Ball et al., 1991). The apparent binding affinity of salmeterol for the b2-adrenoceptor is 
actually lower than formoterol, and formoterol can be slowly washed from airway smooth 
muscle in vitro (Löfdahl et al., 1990), whereas the biological activity of salmeterol persists for 
periods in excess of 10h (Brittain, 1990; Johnson et al., 1993). 
Athletes that regularly use SABAs daily may benefit from using LABAs such as formoterol 
and salmeterol. This will reduce the number of time they use therapy which will improved 
response to rescue inhaler and extend the bronchodilation effect each  time they used the 
LABAs. 
 The duration of a β2-agonists action can be explained by the microkinetic model where 
plasmalemma lipid bilayer of airway smooth muscle acts as a store for b2-adrenoceptor 
agonists with moderate to high lipophilicity. In fact, the balance of evidence currently indicates 
that the membrane itself is a main determinant of the nature of agonist at the b2-adrenoceptor 




solubility), the partition equilibrium is powerfully in favour of the extracellular aqueous 
compartment. As such, the onset of effect is rapid, since the molecule can quickly diffuse to 
the active site of the receptor, but no persistent relaxation of airway smooth muscle occurs 
(Katzung, 2004).  
 
In the case of formoterol, (moderately lipophilic), the partition equilibrium allows the molecule 
to enter the plasmalemma and to be retained. Concurrently, adequate drug is available in the 
aqueous bio-phase to permit immediate interaction with the active site of the receptor, 
accounting for the rapid onset of bronchodilation observed clinically. Subsequently, small 
amounts of formoterol leach out from the plasmalemma and become available for activation of 
the β2-adrenoceptor with a persistent relaxation of airway smooth muscle after wash-out 
(Katzung, 2004). 
 
For highly lipophilic drugs, such as salmeterol, the interaction with the β-adrenoceptor is 
suggested to be energetically unfavourable because the lack of effect of removing the 
epithelium on relaxation time precludes retarded penetration through the epithelium alone as a 













2.5 β2-agonists and the WADA Prohibited List of Substances and Methods 
 
Athletes are allowed only to administer β2-agonists salbutamol, formoterol and salmeterol by 
inhalation. All other routes of administration and forms of BAs are not permitted for use by 
athletes (WADA, 2020). The current WADA restriction on β2-agonists use by athletes has been 
reached over the past four decades. Along with the International Olympic Committee (IOC), 
WADA have continuously modified their rules regarding the use of β2-agonists by athletes in 
and out of competition. In part, this is due to the findings from scientific literature investigating 
the potential ergogenic action of β2-agonists via various routes of administration including 
inhaled, oral and intravenous (Martineau et al., 1992; Collomp et al., 2010; Pluim et al., 2011; 
Decorte et al., 2008; Larsson et al., 1997; Meeuwisse et al., 1992; Le Panse et al., 2006; Caruso 
et al., 2005; McKenzie et al., 1983; Van Baak et al., 2000).  
 
In concomitance with the results coming from the scientific literature, increased use of inhaled 
β2-agonists has been highlighted in the last decades, more specifically between the 1984 Los 
Angeles Olympic Games and the 1996 Atlanta Olympic Games with a 212% increase in the 
use of β2-agonists by athletes (Fitch, 2006). A further increase by 151% was observed between 
the Atlanta games and the 2000 Sydney Olympic Games, leading ultimately to the IOC-
Medical Commission (IOC-MC) decision to change from the requirement for declared use to 
the requirement for objective evidence (indirect or direct airway challenge) of 
bronchoconstriction in 2001, with the health and wellbeing of the athlete being the main 
influencing factor for the decision (TABLE 2.4). The regulations imposed by the IOC were 
largely due to the risk to down-regulate adrenoceptors following repeated supra-therapeutic 
administration of β2-agonists with the risk to become less effective (Fitch, 2006; 2012; 2019; 




Prohibited List of Substances and Methods where the use of inhaled β2-agonists (IBA; 
salbutamol, terbutaline, salmeterol, formoterol) required athletes to provide objective evidence 
of an asthma related condition (e.g. indirect or direct airway challenge) and obtain a therapeutic 
use exemption (TUE; WADA, 2009). This decision was moderately overturned in 2010 when 
salbutamol (1600 µg) and salmeterol were the only permitted IBAs via the declaration of use 
(DoU; WADA, 2010). The percentage of athletes who received a TUE for IBA from the three 
Winter Olympic games (2002, 2006 and 2010) was around 5.2%, 7.8%, 7.1%, respectively 
(Fitch, 2012). The 2010 WADA policy to require athletes wishing to use IBAs to undertake a 
broncho-provocation challenge helped to improve the respiratory care athletes received 
(Dickinson et al., 2005; Dickinson et al., 2011).  
 
In 2011, WADA changed the status of inhaled salbutamol, salmeterol and formoterol; the 
inhaled forms of these drugs became permitted within recommended dosages (salbutamol 1600 
µg/day; formoterol 54 µg/day; salmeterol without the requirement for a DoU; WADA, 2011). 
In addition to this, requirement existing urinary thresholds for salbutamol (1000 ng.mL-1) and 
formoterol (30 ng.mL-1) were delineated with the aim of distinguishing between therapeutic 
inhaled use and prohibited oral use (Ventura et al., 2000; Elers et al., 2011). No threshold levels 
were outlined for salmeterol mainly due to the absence of any oral equivalent. Terbutaline use 
was permitted only through the athlete obtaining a TUE certificate, which had to be obtained 
via the presentation of objective proof of asthma or EIB and demonstrating permitted asthma 
therapy was not providing adequate control of the athletes asthma related condition (WADA, 
2015). 
In 2019, WADA made small modifications in salbutamol doses not allowed to exceed 800 
micrograms over 12 hours starting from any dose; in addition to this, requirement existing 




at 200 micrograms over 24 hours and urinary thresholds for formoterol enlarged to 40 ng.mL-
1 (WADA, 2020). 
 
TABLE 2.4: THE HISTORY OF THE β2-AGONISTS AND THEIR GUIDELINES FOR USE IN THE 
ATHLETIC POPULATION  
 
YEAR History of β2-agonists Guidelines for use in the athletes 
1972 Permission to administer inhaled salbutamol by IOC-MC X 
1975 Inhaled salbutamol and terbutaline with prior notification X 
1976 Olympic team doctors notified IOC-MC of intended use of 
salbutamol or terbutaline 
X 
1980 Permission to use fenoterol by inhalation granted prior to the 
Moscow Olympics 
X 
1984 Fenoterol prohibited at the Sarajevo winter games because of 
metabolism to p-hydroxyamphetamine 
X 
1984 Because of concerns of the effect of air pollution on bronchial 
airways in Los Angeles, team doctors are permitted to notify 
β2-agonists post-administration 
X 
1985 Biltolterol, orciprenaline (isoprotenerol) and rimiterol added 
as permitted β2-agonists. 
X 
1986 Notification of administration of β2-agonists to IOC-MC lo 





1992 Clenbuterol prohibited. Two athletes disqualified in 
Barcellona for using clenbuterol, β2-agonists listed as anabolic 
agents when administered systemically (orally or by injection) 
X 
1993 Biltolterol, orciprenaline, and rimiterol no longer permitted 
β2-agonists. Notification of administration of permitted 
inhaled β2-agonists reintroduced. 
X 
1994 Permission to administer inhaled salmeterol refused by IOC-
MC 
X 
1996 Salmeterol permitted to provide prolonged protection from 
exercise-induced asthma 
X 
2001 Formoterol permitted X 
2001 Because of concerns at the large and increasing number of 
athletes inhaling β2-agonists, as a health measure, the IOC-
MC introduces the necessity for demonstrating that an athlete 
has asthma and/or EIB and is given a therapeutic use 
exemption certificate (TUE) 
X 
2009 The World Anti-Doping Agency establishes regulations for all 
athletes to obtain a TUE for the use of β2-agonists 
X 
2010 Salbutamol and Salmeterol permitted via inhalation with a 
declaration of use. 
X 
2012 Salbutamol, Salmeterol and Formoterol permitted via 
inhalation without declaration of use. Monitoring of 





2012 Terbutaline remains prohibited except when used with a TUE 
certificate 
X 
2017 Dosing parameters of salbutamol were revised; divided doses 
of salbutamol may not exceed 800 micrograms over any 12 
hours. Inhaled salbutamol – max. 1600 mcg over 24 hours. 
X 
2020 Dosing parameters of salmeterol were added; salmeterol may 
not exceed 200 micrograms over hours. Formoterol urinary 
thresholds was enlarged to 40 ng.mL-1. 
X 
 IOC-MC – International Olympic Committee Medical 
Commision; EIB – Exercise-Induced Bronchoconstriction 
X relaxation of guidelines for β2-agonists use 
X stricter guidelines for β2-agonists use 
 
 
2.6 Potential ergogenic action of β2-agonists in athletes 
2.6.1 SABA and endurance performance 
 
Research investigations into the ergogenic action of SABAs have been mainly developed on 
salbutamol and terbutaline administration. The inhalation of therapeutic doses of salbutamol 
has not shown to improve endurance performance in either time trial and time to exhaustion 
(Pluim et al., 2011). Improved VE is a current mechanism observed after the inhalation of 
salbutamol that could be connected with increased maximal oxygen uptake at supra-maximal 
doses (Uren et al., 1993). However, the SABAs inhalation does not appear to significant alter 
VE  or seem not to induce an improvement in aerobic performance when supra-therapeutic 




cycling performance (Koch et al., 2005a; 2005b). Furthermore, a dose of 4000 μg salbutamol 
was not able to rise incremental time to exhaustion or increase the oxygen kinetics in support 
of the absence of a dose-effect relationship (Elers et al., 2012a). 
 
Together these findings suggest that even at supra-therapeutic doses inhaled salbutamol does 
not induce ergogenic action leading to no enhancement of aerobic performance. Moreover, 
high doses of salbutamol could bring side effects (e.g. increased resting heart rate, nausea, 
tremor, dizziness) and the risk to overcome WADA cut-off limits (>1000 ng/mL; Elers et al., 
2012a). 
 
Similarly, inhaling under 15 mg of terbutaline has been shown to not change cycling time trial 
performance (300-Kcal) was recorded when compared to placebo condition (Kalsen et al., 
2014). Despite terbutaline not enhancing time trial performance, it has been shown to increase 
carbohydrate metabolism in skeletal muscles during submaximal exercise regardless AMPK 
and ACC phosphorylation (Kalsen et al., 2014). Moreover, this effect seems to diminish as 
drug exposure time, exercise duration, and intensity increase (Kalsen et al., 2014). Hence, 
increases in carbohydrate metabolism in skeletal muscles observed during submaximal 
exercise could be helpful to improve subsequent high intensity activity as the result of a larger 
amount of glycogen phosphorylase. The incapacity to observe an enhancement in the aerobic 
performance following SABAs administration could be mainly the result of premature 








2.6.2 LABA and endurance performance 
 
Human studies developed to evaluate the ergogenic effect exerted by LABAs on aerobic 
performance are limited; nonetheless studies that have investigated inhaled salmeterol and 
formoterol have reported differing performance outcomes when compared to SABAs (Pluim 
et al., 2011). In support of this, a reduced time to exhaustion performance (3.92 vs 4.11 
minutes) was recorded after inhalation of 54 µg salmeterol when compared to placebo. This 
may be due to an over stimulation of β2-receptors present in skeletal muscle causing an earlier 
onset of muscle fatigue (Carlsen et al., 1997).  The limited evidence on LABAs suggest they 
do not provide an ergogenic action on aerobic exercise performance. Indeed, they may actually 
lead to speed onset of muscles fatigue. However, the ergogenic effect of these drugs has been 
previously assessed only to a very limited extents, further investigation should be conducted in 
order to understand the mechanisms induced by their administration with special attention to 
fatigue development observed during aerobic trials. 
 
2.6.3 Long-term SABAs and LABAs effect on endurance performance 
 
Daily inhalation of 1600 µg salbutamol doses during a 6-week strength and endurance program 
did not improve 3-km running time trial when compared to placebo (Dickinson et al., 2015). 
The nature of the training made of both strength and aerobic training, makes difficult to analyse 
the aerobic performance alone without taking into account the potential overall effects induced 
by the combination of strength and endurance training. 
Especially, long-term administration of terbutaline has been observed to blunt training-induced 
improvements in VO2max when high intensity interval training (HIIT) was performed in 




terbutaline might be the result of the inhibitory effect induced by β2-agonists in cardiovascular 
adaptations, oxidative capacity of mitochondria present in muscles (Holloszy & Coyle, 1984), 
or associated to the high systemic bioavailability induced by continuous adrenergic fight-or-
flight response (Hostrup et al., 2014). Furthermore, long term inhalation of β2-agonists seems 
to attenuate training-induced upregulation of NADH dehydrogenase of the oxidative 
phosphorylation that causes a repression of carbohydrate metabolic pathways such as 
downregulation of glycogen phosphorylase. This effect seems to happen only when repeated 
doses are administered for prolonged time contrary to what observed during acute 
administration (Kalsen et al., 2014). 
 
In summary, endurance performance seems not to be improved by β2-agonists administration 
as shown by the absence of change in maximal oxygen uptake regardless the type of individuals 
(habitual active athletes or resistance trainer athletes (Lemminger et al., 2019). When 
endurance training was performed habitually, β2-agonists blunt upregulation in skeletal muscle 
mitochondrial proteins (Hostrup et al., 2018); conversely, when β2-agonists are administered 
in subjects training for resistance a decrease in mitochondrial proteins in skeletal muscle was 
observed (Lemminger et al., 2019). 
 
Despite endurance performance not to improving after inhaled β2-agonists administration there 
is very limited data on acute use of LABAs and long-term use of LABAs and SABAs that need 








2.7 The effect of β2-agonists administration on body composition  
 
Several studies in the past have demonstrated that β2-agonists injection elicits muscle 
hypertrophy, increases muscle strength, and reduces fat mass in a variety of animals (Emery et 
al., 1984). As a consequence of this, β2-agonists have been applied in hypertrophic model 
systems to examine cellular signalling pathways significant for muscle growth during drug 
administration (Ryall et al., 2006). 
 
Generally, it seems that clenbuterol is the only β2-agonists exerting anabolic and lipolytic 
actions, whereas inhaled β2-agonists prescribed for respiratory disease (i.e. SABAs and 
LABAs) do not show similar responses in terms of fat mass reduction and lean mass 
augmentation (Mottram & Chester, 2018). Clenbuterol is the most used β2-agonists drug 
among bodybuilders (Lynch & Ryall, 2008) because it promotes the production of adrenaline 
hormone in the organism causing an increase in overall body temperature; this increment 
causes thermogenesis and fast lipolysis (Rothwell & Stock, 1987). Therefore, bodybuilders 
experience high perspiration due to the dramatic increase in organism metabolic rate. Although 
LABAs and SABAs are inserted in WADA list of selective and non-selective β2-agonists both 
in and out of competition (S3-category), the anabolic property of clenbuterol places this drug 
in a different category: S1-catergory (WADA, 2020-b). 
 
2.7.1 Anabolic effect induced by SABAs administration 
 
Studies present in literature demonstrate the anabolic effect of short-acting β2-agonists in 
muscle growth when administered chronically as an increase in protein turnover rates in 




administration (Hostrup et al., 2019).  Furthermore, it seems that the increment in protein 
turnover rates is concomitant with increased cAMP/PKA and Akt2, signalling and modulating 
mRNA response of growth-regulating proteins. According to this, the anabolic effect induced 
by β2-agonists administration seems to be dose-dependent with protein synthesis augmentation 
with consecutive days of treatment (Koopman et al., 2010). With regard to this, high doses of 
oral salbutamol (16 µg) have been shown to augment muscle hypertrophic response when 
administered for 14 days during a resistance training program (Caruso et al., 2005). Together 
these results explain observations by Hostrup et al., (2019), demonstrating oral salbutamol 
administration (6 × 4 mg oral) augmented remodelling and recycling myocellular proteins 
process during post exercise recovery period; SABAs administration seems to double the rate 
of protein breakdown and synthesis when compared to placebo. 
 
When β2-agonists are administered in concomitance with resistance training, four weeks 
terbutaline administration has shown to increase lean mass and reducing fat mass in young 
trained men after oral (Hostrup et al., 2015) and inhaled administration (Jessen et al., 2018). 
These observations contrast with outcomes of studies conducted on similar drugs (e.g. 
salbutamol) where no effect on lean body mass was detected after three weeks of oral 
salbutamol (8 mg/twice daily) despite increased muscle strength (Martineau et al., 1992). 
Similarly, after three weeks salbutamol ingestion, no changes in body composition were 
collected in several studies carried out by Le Panse et al., (2005; 2006). The discrepancy in the 
results could be explained by anabolic features that are strongly associated with the class-
specific of the drug.  However, there are not studies comparing the pharmacodynamic and the 
bioequivalence between terbutaline and salbutamol helpful to understand the main differences 





2.7.2 Anabolic effect induced by LABAs administration 
 
When administered chronically formoterol has been shown to increase resting energy 
expenditure and fat oxidation; this effect seems more marked in women than in men by an 
augmented level of leucine turnover (Lee et al., 2015). Notably, not only after oral 
administration but also after inhalation, formoterol increases resting energy expenditure 
(+38%) through free fatty acids mobilisation from white adipose tissue (Hoeks et al., 2003) 
and activates hormone-sensitive lipase in skeletal muscle (Jocken et al., 2008).  
Moreover, when subjects performed exercise at submaximal intensity, formoterol-induced 
increase in energy expenditure was reduced and fat oxidation increased at rest independent by 
subject fat composition and fitness levels (Onslev et al., 2017).  
Currently, the anabolic effect provoked by long-term salmeterol administration has not been 
investigated in literature. Therefore, future investigations into the long-term use of salmeterol 
in combination with resistance training would provide useful data that could inform future 
WADA policy.  
 
 
2.7.3 Anabolic mechanism induced by SABAs and LABAs  
 
SABAs and LABAs elicit anabolic actions binding β2-adrenoceptors with the activation of the 
main signal (cAMP/protein kinase A (PKA)-dependent pathway) that leads to cell proliferation 
and increases protein synthesis. Not only does this signal lead to metabolism regulation and 
gene modifications, but also it leads to cell proliferation, adaption and decreased proteolysis 
(Chen et al., 2000). Therefore, the change in lean mass observed after β2-agonists 
administration is mainly due by a repression in the growth inhibiting protein myostatin and 




Similar to anabolic synthesis, lipolysis involves cAMP/PKA-dependent activation of hormone-
sensitive lipase (HSL) and perilipin A causing catalyses the hydrolysis of triglycerides (Hoeks 
et al., 2003). 
 
2.8 STRENGTH and POWER performance induced by β2-agonists administration  
 
Change in lean mass observed above is likely to lead to the improvement of strength and power 
performance due to an increment in size (hypertrophy) and in the number of muscle fibres 
(hyperplasia; Taylor & Wilkinson, 1986). The majority of the studies conducted investigating 
β2-agonists administration on strength and power are focused on observations of long-term use. 
The effect of SABAs (e.g. albuterol, salbutamol, terbutaline) and LABAs (e.g. fenoterol, 
clenbuterol and formoterol) administration were observed in several studies developed around 
humans and animals (Pluim et al., 2011; McCormick et al., 2010). 
Findings coming from scientific literature are sometimes in contrast with each other, for 
instance maximal voluntary contraction (MVC) of quadriceps has increased after 3 weeks 
administration of 8 mg/day oral salbutamol (Martineau et al., 1992) while similar doses did not 
enhance MVC in endurance athletes (Hostrup et al., 2016). However, Martineau et al. (1992) 
could not explain this change through body weight and lean body mass variations, speculating 
a potential impact on the central nervous system following β2-agonists administration. 
Noteworthy, the discrepancy between these studies could be attributed also to differences in 
subjects training status and in β2-adrenoceptors content that has been shown to be lower in 
athletes organs compared to non-athlete people (Butler et al., 1982). 
Route of administration seems also to contribute to an ergogenic effect following this practice; 
in support of this, similar salbutamol doses reported different results when oral administration 




did not increase strength and power performance in lower and upper body exercise (Dickinson 
et al., 2014). In contrast, the same amount of drug administered orally has shown to increase 
concentric and eccentric power during 9-week resistance training program (Caruso et al., 1995; 
2008).  
 
Similar to the results reported by Caruso et al., (2005; 2008), increased MVC and peak twitch 
force were reported after oral terbutaline (15 µg) by Hostrup et al., (2015). The author 
explained the improvement in 30 s sprint with an increase in lean body mass and muscle 
hypertrophy in the area of myosin heavy chain (MHC) I and (MHC) II fibres. Together these 
results would suggest that the ergogenic features of SABAs on strength and power performance 
seems to act mainly after chronic oral acute administration without observing changes in the 
number of muscle proteins (Hostrup et al., 2016; Sanchez et al., 2012). Similarly, when oral 
salbutamol has been administered in concomitance with strength training, significant maximal 
anaerobic power was recorded in the group undertaking oral salbutamol on daily bases 
regardless subjects' training status. A significant increment in peak power and strength was 
observed in strength-trained subjects (+11.9 %) and sedentary subjects (+8.3 %) without 
reporting change in lean body mass and fat mass (Le Panse et al., 2005). 
 
In conclusion, there is potential for ergogenic action on strength and power performance 
following long-term administration of β2-agonists as observed with SABAs oral 
administration. Future investigations should incorporate the impact of LABAs administration 







2.9 SPRINT performance induced by IBAs 
2.9.1 Sprint performance induced by SABAs 
 
Sprint improvements following the administration of β2-agonists have been mainly observed 
following the administration of prohibited substances and methods present in the list of WADA 
(WADA, 2020).  Increased sprint performance was reported after inhaled terbutaline (15 mg) 
administration (Kalsen et al., 2016; Hostrup et al., 2015) and oral salbutamol administration 
(Hostrup et al., 2016; Sanchez et al., 2012; Collomp et al., 2010; Le Panse et al., 2005; Le 
Panse et al., 2006). An increased rate of Ca2+ release and re-uptake from the SR in skeletal 
muscle seems to have improved power output in the above studies. Moreover, augmented 
Na+_K+ATP_ase activity may have also contributed to the higher power output recorded by 
counteracting loss of membrane excitability via an increased re-uptake of K+ from the 
interstitium (Sejersted & Sjøgaard, 2000). In addition to this, accelerated rate of ATP 
resynthesise has been observed to be significantly augmented after the administration of β2-
agonists (Allen et al., 2008). Notably, even after supra-therapeutic salbutamol doses ATP 
resynthesise is not increased probably because low doses are not able to stimulate β2-
adrenoceptors sites present in the body needed to induce an increase in glycolytic mechanism 
(Lemmer et al., 1995; Meeuwisse et al., 1992; Morton et al., 1993).  
 
When inhaled for 6 weeks, salbutamol did not show an increase in power performance when 
inhaled in parallel with strength and aerobic training program (Dickinson et al., 2014); this 
could be linked with β2-adrenoceptors down-regulation that decrease both the density and 
sensitivity of β2-adrenoceptors (Butler et al., 1983). In support of this, the reduced effect 
observed on sprint performance following 3-weeks administration compared with acute 




effect of salbutamol provoked by repeated β2-agonists administration. Interestingly, when low 
oral doses (8 µg) were administered for 2-weeks β2-adrenoceptors down-regulation seems not 
to take place as shown by a significant enhancement on sprint performance (Hostrup et al., 
2016).  
 
In conclusion, increased sprint performance has been observed after terbutaline and salbutamol 
oral administration in both acute and chronic; however, this effect does not happen after the 
inhalation of supra-therapeutic doses of SABAs.  
 
2.9.2 Sprint performance induced by LABAs 
 
The effect provoked by LABAs administration on sprint and power performance is limited in 
scientific literature. It seems that acute formoterol inhalation (54 µg) is able to enhance 
maximal voluntary contraction and power output during maximal sprint activity (Kalsen et al., 
2016); however, this effect seems to be strongly correlated with the amount of drug inhaled 
because the same sprint activity did not record a change in performance after 27 µg of 
formoterol (Stewart et al., 2002) or after 42 μg of salmeterol (McDowell et al., 1997). 
McDowell (1997) did not report significant difference changes in blood lactate concentration 
between salmeterol and to placebo condition suggesting insufficient stimulation of β2-
adrenoceptors. 
After high doses of LABAs, increased release of Ca2+ from the ryanodine receptor 1 (RYR1) 
of the sarcoplasmic reticulum (SR) has been documented to enhance force production (Hostrup 
et al., 2014) and prevent loss of membrane excitability through the stimulation of 






In conclusion, it seems that even at supra-therapeutic doses allowed by WADA, SABAs 
inhalation is not able to induce an ergogenic effect on strength and power activities. In addition 
to this, chronic inhalation of salbutamol is associated with side effects and seem to provoke 
down-regulation in β2-adrenoceptors. Therefore, the attempt to increase the systemic 
concentration of β2-agonists in the body through repeated inhalation of SABAs in consecutive 
days seems not able to induce change in strength and power performance. Conversely, 
formoterol has been observed to enhance sprint power output and maximal voluntary 
contraction during 30-s sprint. Whether the cause of augmented performance could be mainly 
associated with increased glycolytic activity, the smaller drop observed in MVC after the sprint 
could be linked to fatigue resistance features of LABAs. In support of this, LABAs 
administration increase the rate of Ca2+ release and Na+_K+ATP_ase that counteract the muscle 
fatigue experienced by repeated sprint activities. 
 
2.10 Overall Summary 
 
Athletes are lightly to experience EIB due to the high ventilatory demands required by the 
practice; it is not uncommon for these athletes to be diagnosed with exercise-induced asthma 
or exercise-induced bronchoconstriction. Therefore, prescription of IBAs represents the first 
choice to reverse these symptoms. However, some SABAs and LABAs may provide an 
ergogenic action when administered in “non-asthmatic” subjects even at doses allowed by 
WADA where a therapeutic use exemption is not mandatory. 
 
The administration of SABA seems not improve endurance performance in either inhalation or 




designed around LABAs administration have been mainly developed using salmeterol without 
finding an ergogenic effect when endurance performance was developed. Furthermore, the 
stimulation of β2-receptors present in skeletal muscle following LABAs could induce a 
prolonged effect compared to SABAs without provoking β2-adreceptors down-regulation. 
Moreover, from the inhalation of supra-therapeutic doses of SABAs and LABAs an increment 
of the glycolytic metabolism has been recorded with high level of blood lactate collected.  
Strength performance performed after SABAs administration seems to be increased only after 
chronic oral salbutamol administration without changes in muscle proteins and maximal 
voluntary contraction were recorded. SABA administration regardless the amount of drug 
inhaled does not appear to increase strength performance even at supra-maximal doses. Due to 
the absence of studies observing the effect of LABAs administration on strength performance, 
future studies need to be developed around this field even in concomitance with long-term 
LABAs administration. According to this, the observation of LABAs administration and 
training would mimic real-life strategies experienced by athletes training for strength 
improvements. 
 
The enhancement in strength following SABAs oral administration could be explained through 
the increase in body composition; in fact, change in hypertrophy and lipolysis has been 
observed after daily oral salbutamol administration when the drug was administered at least for 
2-weeks. However, this effect seems not to happen after supra-therapeutic inhalation of 
SABAs. Similarly, LABAs formoterol has shown to increase fat oxidation and fat mobilisation 
expressed by increased energy expenditure that was more marked in women than in men. 
Currently, there are not studies looking at anabolic effect of salmeterol and formoterol when 





An increase in sprint performance following SABAs administration has been observed only 
after oral terbutaline and salbutamol administration but not after others way of administration 
mainly due to the lower amount of β2-agonists present in the systemic circulation after 
inhalation. The inhalation of LABAs increased power output during maximal sprint activity 
after high dose of formoterol (54 µg); contrarywise, low doses were not able to record similar 
change of performance even when after the inhalation of salmeterol. 
 
Notably, no studies present in literature have looked at the effect of LABAs administration on 
sprint performance during fatigued condition. Therefore, the need to test the ergogenic effect 
of LABAs administration in acute fatigue and in chronic fatigue could add extra info helping 
to understand long-acting β2-agonists mechanisms.  
 
 
2.11 AIM of the Thesis 
 
 
I. To investigate the effect of supra-maximal dose of inhaled salbutamol (1600 µg) on 
running sprint ability in “non-fatigued” and “fatigued” state performed before and 
after the Yo-Yo IRT. Moreover, total distance cover and physiological measures 
collected during Yo-Yo IRT will be analyse in order to observe any ergogenic effect 
induced by SABAs. 
 
II. To investigate the effect of high-dose inhaled salmeterol (100 µg) on 12-s maximal 
sprint in high-level cyclists. Immediately after the sprint, one-hour Variable cycling 




during the Gran Tour stage. The increment in power output throughout the Variable 
cycling trial will increase participants levels of fatigue before 12-s sprint 
performance will be repeated at the end of the session. Power output recorded during 
the sprints and physiological measure collected during the aerobic trial will be then 
analysed and compared with placebo condition. 
 
III. To investigate the effect of daily administration of inhaled LABAs salmeterol (100 
µg) and formoterol (12 µg) during 5-week of strength and power training program 
performed by recreational active individuals 3-times a week. Maximal strength, 
sprint performance, jump height and body composition will be assessed at the 
beginning and at the end of the programme in order to observe any performance and 
physiological changes provoked by daily LABAs when compared to placebo group.  
 
 
2.12 HYPHOTHESIS of the Thesis 
 
 
I. Chapter 4 hypothesis is that daily doses of LABAs could increase strength and 
power performance when developed in concomitance with a resistance training 
program. This will allow subjects to lift heavier weights during training sessions 
with a possible increment also in sprint performance as consequence of better muscle 
synchronisation and lean mass augmentation.  
 
II. Chapter 5 hypothesis is that after supra-maximal salbutamol dose will increase both 
maximal sprint ability in “non-fatigue” condition (before the Yo-Yo IRT) and in 




significant difference in the distance covered during the intermittent aerobic trial due 
to the observations present in literature that did not show SABAs effectiveness on 
aerobic performance.  
 
III. Chapter 6 hypothesis is that salmeterol inhalation will record a significant 
increment in both the 12-s sprint performed in “non-fatigued” and “fatigued” 
conditions performed before and after the Variable cycling trial when compared with 
placebo conditions. In addition to this, I’m expecting to find a marked difference 
between conditions especially during the final sprint performed at the end of the 















































This chapter will explain the assessment tests that were adopted for every experimental study 
in this thesis and will be discussed. The current, extended method for each experiment can be 
read in the methodology section of each study chapter. 
 
3.1 “Spirometry test” 
 
Spirometry is a medical test used to measure the volume of air that an individual inhales or 
exhales as a function of time (Miller et al., 2005). In the following collection of studies forced 
vital capacity (FVC) manoeuvres were performed exclusively. FVC is the maximal volume of 
air exhaled with maximally forced effort from a maximal inspiration (Miller et al., 2005). The 
American Thoracic Society (ATS) and the European Respiratory Society (ERS) has published 
guidelines for the measurement of lung function (Miller et al., 2005), which were respected 
when spirometry measurements were performed.  
 
Throughout the studies maximal flow volume loops were collected using either of the 
following turbine spirometers: SpiroUSBTM (Carefusion 234 Germany GmbH) or MicroLab® 
Spirometer (Carefusion 234 Germany GmbH).  
Participants were asked to assume the correct posture (FIGURE 3.1) and sat upright in a chair, 
wore a nose clip to prevent nasal breathing and were instructed to reach maximum inhalation 
before placing the spirometer mouthpiece in the mouth and forcefully exhaling as hard as they 
could.  
Breathing out continued until they had completely emptied their lungs; this point was indicated 
by a plateau in the volume/time graph on the spirometer, at which point the experimenter would 
encourage the participant to breathe in as fast as possible to maximum inspiration, completing 




A minimum of three maximum attempts were required for baseline measurements, flow-
volume measurements were rejected if: the participant was considered not to have reached 
maximum inspiration prior to the maneuver; the participant manifested obstructions such as 
cough during the maneuver; the participant was believed to have performed a slow start or to 
have not maintained the pressure of expiration for the duration of exhalation and also if the 
values were not coherent (i.e. large variability among the three baseline values). 
 
Flow-volume measures recorded from each maximal flow-volume loop were;  
Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC), FEV1 to FVC 
ratio (FEV1/FVC %), Peak Expiratory Flow (PEF) and forced expiratory flow between 25% 
and 75% of FVC (FEF25–75). Individual maximal flow-volume loops were accepted in 
accordance with European Respiratory Society American Thoracic Society criteria (Miller et 

















FIGURE 3.1 MAXIMAL FLOW-VOLUME LOOP ACCEPTANCE CRITERIA 
 
Adapted from Miller et al., (2005) 
 
3.2 “Eucapnic Voluntary Hyperpnoea Challenge”  
 
All participants underwent a eucapnic voluntary hyperpnoea (EVH) challenge in accordance 
with the methods described by Anderson et al., (2001). Participants were instructed to avoid 
intense exercise the day of the test. Due to the bronchodilator effects of caffeine (Duffy & 
Phillips, 1991), participants were inquired to avoid consumption of caffeine-containing 





 If an athlete was suffering from an illness that may limit the results of the test, they were asked 
to return when they were well and fit to complete the test. Baseline FEV1 was recorded from 
three maximal voluntary flow-volume maneuver. Whether the participant had an FEV1 less 
than 80% of the predicted value or if they had an FEV1/FVC ratio less than 70% they were 
excluded from participation in any studies.  
Participants were asked to attain target minute ventilation (V_̇E) of 85% (FEV1 x 30) of their 
predicted maximal voluntary ventilation rate (MVV) for 6 minutes (Anderson et al., 2001). 
During the 6 minutes, participants breathed air from a compressed gas cylinder containing 21% 
Oxygen (O2), 5% Carbon Dioxide (CO2) and 74% Nitrogen (N2) with inspired air temperature 
19°C, and humidity < 2%. Annotation the 5% CO2 concentration in gas to maintain eucapnia 
and prevent participant from the adverse effect of prolonged hyperventilation, such as dizziness 
















The gas was delivered to each participant via a gas cylinder, reservoir and a two-way valve; VE 
was recorded by calculating the volume of air passing through a dry gas meter every minute 
(FIGURE 3.2).  
            










Gas cylinder (1), regulator (2), demand resuscitator 30-150 L/min (3) high pressure tubing (4),      rotameter 
(5), three-way tap (6), Douglas bag (7), wide bore tubing (8), large low resistance low dead space two-way 
valve (9), gas meter (10). 
 
During the EVH challenge verbal feedback was provided to the participant in order to 
encourage them to meet their target V̇E. 
After the 6-minute EVH challenge, two maximal voluntary flow-volume loops were measured 
at 3, 5, 7, 10 and 15-minute time-points, with the highest of the two FEV1 values recorded. A 
fall in FEV1 greater than 10% on two occasions post-challenge resulted in a positive test. The 
grade of a positive EVH-challenge was graded as mild, moderate or severe if the percent fall 
in FEV1 from baseline values were ≥ 10% but < 25%, ≥ 25% but < 50% and ≥ 50%, respectively 




Following the test participants that did not reach FEV1 baseline levels within 15 minutes after 
stopping the activity were offered 400μg inhaled Salbutamol to assess their reversibility to 
bronchoconstriction. Spirometry was performed 15 minutes post-inhalation of Salbutamol 
(Miller et al., 2005). A positive bronchodilator response (reversibility) was defined as an 
increase of ≥ 12% and 200 ml in post-EVH FEV1 and/or FVC (Miller et al., 2005). 
 
3.3 “Peak Oxygen Consumption (VO2peak)” 
 
Participants completed an incremental cycling exercise test (2 min at 50 W + 50W/ 2 min) until 
voluntary exhaustion or until pedal frequency fell below 60 revolutions/min (RPM) for more 
than 5 s to establish peak oxygen consumption (VO2peak; Withers et al., 2000). This test was 
performed on an electromagnetically braked cycle ergometer (Excalibur Sport, Lode, 
Groningen, The Netherlands).  Prior to starting, the participants were fitted with a heart rate 
monitor (Polar RS400; Polar Electro Oy, Kempele, Finland) and connected to a breath-by-
breath online gas analyser via a face-mask (MetaLyzer 3B, Cortex Biophysik, Leipzig, 
Germany). At the end of every stage and upon trial cessation the following were measured: 
time (s), heart rate (HR), oxygen consumption (VO2), carbon dioxide production (VCO2), 
minute ventilation (VE), respiratory exchange ratio (RER) and rating of perceived exertion 













Chapter 4. Improved Sprint 
Performance With Inhaled Long-Acting 





















The 2019 World Anti-Doping Agency (WADA) permits athletes to use inhaled therapeutic 
doses of β2-agonists salbutamol (1600 μg/d, no more than 800 μg in a 12-h period), formoterol 
(54 μg/d), and salmeterol (200 μg/d). However, there is some debate as to whether the current 
rules allow unscrupulous athletes, with and without asthma-related conditions, to use inhaled 
β2-agonists for the purpose of benefitting from a potential ergogenic action. 
Previous research investigating the acute and short-term use (e.g. 2 weeks) of inhaled β2-
agonists suggests they do not have an ergogenic action on endurance performance (Pluim et 
al., 2011). Furthermore, endurance performance is not improved from acute doses of inhaled 
formoterol (Tjørhom et al., 2007) and salmeterol (Sue-Chu et al., 1999). However, moderately 
and highly trained individuals may experience enhanced strength and power performance from 
the acute use of short acting (Hostrup et al., 2014) and long acting β2-agonists (Kalsen et al., 
2016). 
The mechanisms behind the ergogenic action from acute doses that have been observed in 
skeletal muscle include: β2-adrenergic stimulation that counteracts exercise-induced reductions 
in Na+-K+ ATPase maximum rate of activity, elevated glycolytic activity during high intensity 
exercise and enhanced rates of Ca2+ release and uptake from the sarcoplasmic reticulum 
(Hostrup et al., 2014). Furthermore, increased anaerobic ATP utilisation has been suggested as 
a potential mechanism (Kalsen et al., 2016). However, others have failed to demonstrate 
changes in peak velocity and have shown maximal strength deteriorates following acute oral 
terbutaline administration (Sanchez et al., 2013). Long-term use of β2-agonists also has the 
potential to produce an ergogenic action. Data from animal models suggests long-term β2-
adrenergic stimulation results in muscle hypertrophy (Burniston et al., 2006). Studies 
investigating the long-term β2-adrenergic stimulation in humans suggest increases in skeletal 




protein synthesis (Lee et al., 2013) may occur. Furthermore, salbutamol has been shown to 
counteract a negative net protein balance following resistance training in males (Hostrup et al., 
2018). These changes to skeletal muscle from long-term use of β2-Agonists (8mg/d oral 
salbutamol for 2 week) has been shown to increase peak muscle strength (Hostrup et al., 2016) 
and power output, (Hostrup et al., 2015) whilst also inducing a slow-to-fast twitch muscle 
phenotype transition in humans (Hostrup et al., 2018). 
Long-term use of terbutaline (4mg/d for 4 week) may also decrease body fat due to increased 
fat mobilization from adipose tissue (Hostrup et al., 2015), decreased fat synthesis in adipose 
tissue and liver (Onslev et al., 2017), or a combination of both (Yang et al., 1989). Although 
there is clear potential for ergogenic action with oral or supra-therapeutic inhaled doses of β2-
agonists, we do not know whether long-term stimulation of β2-adrenoreceptors via therapeutic 
doses of long acting inhaled β2-agonists has a similar effect. 
Endurance training has been shown to confound the ergogenic action of inhaled short acting 
β2-agonists (Dickinson et al., 2014). However, the ergogenic action of inhaled short acting β2-
agonists is augmented with resistance training (Jessen et al., 2018). It is not known whether 
there is a similar interaction when long acting β2-agonists are inhaled whilst engaging in 
strength training. This is a realistic consideration as athletes using long acting inhaled β2-
agonists (salmeterol or formoterol) are prescribed to do so on a daily basis, which may modify 
their response to strength and power training. 
Therefore, the hypothesis behind this study is that repeated doses of β2-agonists could mimic 
the effect provoked by oral route when developed in concomitance with a resistance training 








4.2.1 Study Participants 
I initially recruited twenty-four male participants however one male participant withdrew from 
the study due to an injury not related to the study in week four.  
I therefore had twenty-three healthy recreationally active males (mean ± SD: age 27.9 ± 5.5 
years; height 179.8 ± 7.3 cm; weight, 78.8 ± 10.3 kg) and fifteen recreational active females 
(age 24.1 ± 4.1 years; weight 65.4 ± 9.5 kg; height 168 ± 4.3 cm) who volunteered for the 
study, provided informed consent and completed the study.  
All participants have been involved in strength and power activities over the past year during 
their weekly training habits. The heterogeneous nature of the male participants taking part in 
the study was characterised by their involvement in a variety of sports at an amateur 
competitive level including: football (n = 9); basketball (n = 4); track and field (n = 2); martial 
arts (n = 3); swimming (n = 1); running (n = 2); and cycling (n = 3). Female participants were 
characterised by their involvement in a variety of sports at an amateur competitive level 
including: basketball (n = 8); football (n = 4); boxing (n = 2); running (n = 1).  
Prior to participation in the study none of the participants completed in strength and power 
lifting sports. Participants engaged in strength and power training sessions at least three times 
per week completing a diary to record their training engagement and progress. 
The participants completed all assessments at the same time of the day (within 1 h), separated 
by a minimum of 48 hours. They were instructed to sleep for at least 7 hours, drink at least 35 
mL/kg/day of water, refrain from consumption of alcohol for 24 hours prior to the visit and 







4.2.2 Broncho-provocation Challenge 
All participants were free from asthma and EIB, which was confirmed by the presentation of a 
negative EVH challenge (Anderson et al., 2001).  
 
4.2.3 Treatment Groups 
Participants were randomly assigned to one of three groups using a minimisation method (Scott 
et al., 2002). As part of this randomisation we factored in gender balance between groups so 
that they were balanced eight males to five females in each group. In a single blinded 
randomised design each group was allocated to use either:  
 
• Placebo inhaler (containing water vapor) twice daily (PLA)  
• Inhaled 100μg salmeterol twice daily (Serevant, Accuhaler 50 μg/dose, GSK, UK)  
• Inhaled 12μg formoterol twice daily (Oxis Turbohaler 6 μg/dose, Astra Zeneka, UK)  
 
These doses were chosen as they are high therapeutic doses permitted for use by athletes 
(WADA, 2019). Participants were instructed about their inhaler technique. At each training 
session researchers checked the participants were using their inhalers as instructed by reading 
the inhalation counter on their device to confirm they were adhering to the protocol. 
 
4.2.4 Assessments 
Participants completed each of the following assessments at baseline and one week after the 
final inhaler dose and training session. Prior to the start of the study participants attended two 






4.2.5 30 Meters Sprint 
Participants were asked to complete a maximal 30 m sprint on a non-motorised calibrated 
treadmill (Force Treadmill System, Woodway, SA). The peak speed data collected from the 
non-motorised treadmill has been described in literature to be approximately 80% of that 
achieved in free-sprint track performance (Morin et al., 2011). Each participant completed 
three 30 m sprints separated by 5 minutes. The fastest 30 m sprint was recorded. 
 
4.2.6 Isokinetic Dynamometry 
Participants performed three maximal voluntary contractions of the knee extensors at 120°.s-1 
and three maximal voluntary contractions of the knee flexors at 120°.s-1 (Biodex 830-210, 
Biodex Medical System, Shirley, New York, USA). The highest peak torque measurement was 
taken as a measurement of maximal strength in the knee extensors and knee flexors.  
 
4.2.7 Maximal One Repetition Bench Press and incline Leg Press  
Participants progressively worked toward a maximum one repetition for both incline leg press 
and bench press. The incline leg press (CF800 Leg Press/Hack Squat Machine, Bodymax, UK) 
was performed at 45° by first completing a six-repetitions maximum. This was followed by a 
four-repetition maximum and a two-repetition maximum at increasing weights. The bench 
press was performed using a 20 Kg Olympic bar with weights added to it accordingly. The 
participants continued to complete one-repetition efforts at increasing weight until they reached 
failure. Each effort was separated by four minutes (Willardson et al., 2006). The weight lifted 








4.2.8 Power – Counter Movement Vertical Jump (CMJ) 
A counter movement jump was performed on a jump mat (Probiotics Inc., Huntsville, AL, 
USA). The participants were instructed to jump as high as they could by performing a CMJ 
with an arm swing. Coaching of technique was only provided if participants consistently landed 
off the jump mat demonstrating poor technique. Participants performed three counter 
movement jumps and the greatest vertical jump height achieved was recorded.  
 
4.2.9 Body Composition  
Skin-fold thickness was taken at the following recognised sites on the right-hand side of the 
body: triceps, biceps, subscapular and supraspinale. All measurements were taken by the same 
technician using a single set of Harpenden skinfold callipers (Baty International, Sussex, UK). 
Skin-fold thickness measurements were taken from each site consecutively a total of two times 
with the mean of the two measurements taken as the skin fold thickness for each specific site. 
The criterion for a valid measurement was a difference of less than 1 mm between the two 
totals. If this was not the case the measurements were repeated until the criterion was met. The 
sum of four mean skin-folds thickness measurement was calculated. 
 
4.2.10 Recovery, Sleep and Mood Questionnaires 
Participants completed questionnaires in week three and five to measure recovery and stress 
from training and mood. Recovery and stress from training were assessed via the Recovery-
Stress Questionnaire for athletes (Kellmann et al., 2010). Mood was assessed using the Brunel 







4.2.11 Strength and Power Training Program 
Following the completion of the above baseline assessments participants began a strength and 
power training program. The training program focused on developing strength, power and 
sprinting. Participants training was individualised and supervised by a strength and 
conditioning specialist. 
Participants training incorporated lower body exercise such as lunges, squat, leg press and leg 
curl; upper body exercises included chest and shoulder press, shoulder dumbbell raise and arm 
exercises using both barbell and dumbbells. Each training session consisted of twelve 
exercises. Each exercise was completed with a target of completing three sets of eight 
repetitions, with each set separated by two minutes. When participants were able to complete 
all three sets they increased the load. Sprint training included exercises involving quickness 
and coordination with a set of 5 to 10 m sprint accelerations performed five times at the end of 
the training session. Participants recorded total work done during each session. 
Participants were asked not to engage in strength, power or sprint training outside of the 
program. Aerobic training outside of the study was restricted to two sessions per week. It was 
not feasible to accurately record or control for the intensity and duration of any additional 
endurance-based training. 
 
4.2.12 Statistical Analysis 
Changes in sprint performance, strength, power, mood, recovery, sleep and skinfold thickness 
from baseline to week five between PLA, SAL and FOR were analysed using repeated 
measures ANOVA (3 group x 2 time).  
Assumptions for this analysis was checked and corrected for according to the methods 






A p < 0.05 was deemed significant. Effect size was calculated according to Cohen’s statistical 
power analysis used to indicate the standardised difference between two means measuring 


























4.3.1 Baseline Groups Comparison  
There were no differences at baseline between groups for any of the sprint (p=0.670), strength 
and power (p=0.226), anthropometric (p=0.438) and skinfolds (p=0.762). Psychological 
variables were different at baseline (p=0.001) but not at week 3 and week 5 between groups 
(p=0.234). 
 
4.3.2 30 Meters Sprint  
Between baseline and week five 30 m sprint time improved in both the FOR (–0.29 ± 0.11 s; 
p=0.049; ES= 0.50) and SAL (–0.35 ± 0.05 s; p=0.040; ES= 0.41) groups when compared to 
the placebo group (+0.01 ± 0.11 s); (FIGURE 4.1). 
 
FIGURE 4.1 “30 METERS SPRINT IN SAL, FOR AND PLA” 
 







4.3.3 Strength and Power Assessments 
Over the five weeks all groups improved markers of strength and power (TABLE 4.1). There 
was no difference in the rate of improvement between groups. 
 
TABLE 4.1 “30 METERS SPRINT, POWER & STRENGTH PERFORMANCE IN SAL, FOR & PLA” 




















































































































































Abbreviations: 1RM = one maximal repetition; SAL = salmeterol; FOR = formoterol; PLA = placebo * = 
Significantly different from PLA (p < 0.05). Incline Leg press 45°, Hack Squat and Bench Press measured is 
reported at 1RM; Leg Extension, Leg Flexion is reported as Peak Torque measured at 120o.s-.a. Data are presented 





4.3.4 Anthropometric Measures  
Over the five weeks of training the sum of skinfold thickness across four sites did not change 
significantly (p=0.762; TABLE 4.2). No significant changes in body mass between groups 
were observed over the five weeks of training (p=0.915; TABLE 4.2). 
 
TABLE 4.2 “SKINFOLDS & BODY MASS in SAL, FOR AND PLA” 
 SAL FOR PLA 
 






































Abbreviations: S4 = Sum of the four skinfold sites (triceps, biceps, subscapular and supra-spinale); RM = 
repetition maximum; SAL = salmeterol; FOR = formoterol; PLA = placebo. DATA Aare presented at week 0 to 
week 5. Mean ± SD 
 
4.3.5 Recovery, Sleep and Mood Questionnaires  
Recovery-Stress Questionnaire index did not change (p=0.395) across the five-week training 
period in PLA, SAL or FOR groups (TABLE 4.3). 
 
TABLE 4.3 “REST Q RECOVERY & STRESS INDEX IN SAL, FOR AND PLA” 
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My study suggests that 30 m sprint performance is improved when daily doses of inhaled 
formoterol or salmeterol are combined with strength, power and sprint training over a five-
week period. However, I did not observe significant changes in strength, power, mood, 
recovery or skinfold thickness between formoterol, salmeterol and placebo over the five-week 
period. The improved 30 m sprint performance following five weeks of inhaled formoterol or 
salmeterol administration in our study was similar to previous reports examining acute and 
long-term use of β2-agonists. Likewise, administration of oral β2-agonists enhances muscle 
strength and peak power output during maximal cycling (Martineau et al., 1992; Le Panse et 
al., 2005; 2006). Improvements in sprint and power performance from short-term use of β2-
Agonists has been suggested to be as a result of increased skeletal muscle mass and maximal 
muscle force production, leading to greater initial peak power (Hostrup et al., 2015). 
Furthermore, high doses of formoterol can augment resting energy expenditure and fat 
utilization in active males (Lee et al., 2013). However, in some cases where authors report 
changes in peak power this does not correspond to significant improvements in the mean power 
produced during a Wingate test (Hostrup et al., 2016). Although Wingate performance is 
related to sprint performance, the duration of our 30 m sprint was approximately seven seconds 
compared to the 30-s Wingate challenge. It may be long-term use of formoterol and salmeterol 
have a greater potential for ergogenic action for explosive sprints lasting under 10 s, compared 
to longer sprinting activities. Further research is required to confirm this hypothesis.  
In my study although I observed sprint performance improvement not supported by changes in 
strength, power or skinfold thickness. This may due to the smaller therapeutic doses of 
salmeterol and formoterol use in our study, compared to other studies using supra-therapeutic 




may not have been sensitive enough to detect changes in muscle mass. By using other means 
of measuring changes in body composition (e.g. DEXA) I may have detected changes in muscle 
mass. In a recent study by Jessen et al., (2018) a significant increase in lean body mass of 1.03 
– 1.04 kg was observed with DEXA.  
Gender differences in pulmonary anatomy may influence the potential ergogenic action of 
formoterol and salmeterol. Although previous studies that have suggested this may be the case 
for salbutamol, the hypothesis has not been rigorously investigated (Koch et al., 2015a). Due 
to the relatively small number of females in my study, my data was underpowered to conduct 
meaningful sub analyses.  
Future studies should investigate the relationship between long acting β2-agonists 
administration in male and female athletes and the bio-availability required to stimulate an 
increase in muscle protein turnover and synthesis between sexes. Previous studies suggest 
formoterol induces opposing effects between oxidation and synthesis but ultimately results in 
net anabolic gain because of a greater anti-catabolic effect (oxidation) over reduced synthesis 
(Lee et al., 2013). In females, these anti-catabolic and synthesis effects were three-fold larger 
when compared to men (Lee et al., 2013). 
Previous studies have demonstrated that the potential ergogenic action of long-term use of β2-
agonists can be confounded by endurance training (Jessen et al., 2018). In my study I 
specifically focused on strength and power training that has previously been shown not to 
confound increases in lean mass. We have not investigated whether endurance training would 
confound the improvements in 30 m sprint performance, which has been previously reported 
when short acting β2-agonists have been used over a four to six-week period incorporating 
endurance training (Dickinson et al., 2014). 
Athletes use formoterol and salmeterol to protect against bronchoconstriction. Both drugs have 




It is not known whether athletes using either inhaled formoterol or salmeterol increase the risk 
of these side effects. However, in our study we did not observe athletes reporting these 
symptoms throughout the study. Furthermore, we did not see any significant differences 
between the recovery, sleep and mood between groups parameters to see if salmeterol or 
formoterol may have influenced perception of recovery between training days. As we have not 
detected any differences between groups, we can exclude this as a potential mechanism to 
explain improvements in 30 m sprint performance. 
 
4.4.1 Limitations 
A limitation of this study is that I cannot assume the observations I have seen in my participants 
who take part in recreational sport translate to elite athletes. However, if elite athletes did take 
part in my study they may have been subject to a doping test, in which they may have provided 
a urine sample with a concentration of formoterol that is above the permitted level and therefore 
committed an anti-doping violation. For this reason, I excluded elite athletes from participating. 
Future studies may incorporate highly trained individuals to investigate whether they 
experience a similar response to sprint performance following five weeks of inhaling either 













This study was the first to demonstrate five weeks of therapeutic doses of either inhaled 
salmeterol or formoterol in combination with strength, power and sprint training may improve 
30 m sprint performance. At this stage I am not able to conclude that similar effects will occur 
in highly trained athletes using similar doses. Therefore, anti-doping stake-holders may wish 
to commission investigations into whether highly trained athletes experience a similar 
ergogenic action from inhaled formoterol or salmeterol. These studies should be conducted 
before changes to the WADA Prohibited List are recommended. However, these findings 
suggest that consideration should be given to closer monitoring of inhaled long acting β2-
agonists use by athletes in and out of competition. Future research is required to investigate the 











Chapter 5. The Effect of 1600 µg Inhaled 
Salbutamol Administration On 30 Meter 
Sprint Performance Pre and Post a Yo-















Athletes with asthma related conditions are permitted to use inhaled salbutamol in accordance 
with current WADA regulations (WADA, 2019). Although a therapeutic dose of inhaled 
salbutamol ranges from 200-400 µg, football players are permitted to inhale up to 800 µg in 
any 12 hours period and 1600 µg in a 24 hour period without a TUE. Limited data is available 
to explain whether football players may gain an ergogenic advantage from doses of inhaled 
salbutamol up to 1600 µg. 
 
Recent research by Dickinson et al. (2015) suggests that doses of up to 1600 µg of inhaled 
salbutamol do not improve repeated sprint performance following a 52-minute football specific 
treadmill running protocol. However, others have observed improvement in sprint cycling after 
the inhalation of salbutamol 180 µg (Signorile et al., 1992) and 15 mg terbutaline (Kalsen et 
al., 2016). The latter authors suggested the improved 10 s sprint cycling performance was 
associated with a greater fatigue resistance in type II fibres due to increased rates of 
glycogenolysis and glycolysis. Furthermore, it has been shown when well-trained swimmers 
inhale a combination of Salbutamol (1600 µg), Formoterol (36 μg) and Salmeterol (200 µg), 
their 100 m sprint performance is enhanced maybe due to high systemic concentration reach 
through repeated doses of β2-agonists (Kalsen et al., 2013). Recently, Hostrup et al., (2016) 
demonstrated that initial Wingate sprint performance was enhanced after 8 mg oral salbutamol 
administration but subsequent sprints were not enhanced in the same way. However, in the 
same study after two weeks daily administration of 8 mg oral salbutamol, a significant effect 
in sprint performance has been recorded in the first two performances.  
 
Therefore, the ergogenic action demonstrated in the previous studies after acute use of short 




limited data to assess whether sprint performance is enhanced with prior inhaled salbutamol 
after a fatiguing football protocol. The purpose of this study is to investigate the potential 
ergogenic action of inhaled 1600 µg salbutamol on 30-m sprint performance in football players 
before and after the Yo-Yo test (Yo-Yo IRT Lev1). 
 
5.2 Methods 
5.2.1 Study Participants 
Thirteen male (mean + SD; age 18.1 + 0.9 years; weight 69.5 + 8.3 kg; height 178.0 + 6.5 cm; 
VO2max 51.2 ± 3.4 mL min-1 kg-1) football players volunteered and provided written and verbal 
informed consent. All players took part in amateur football league, competing once a week and 
trained specifically for football at least three times a week (mean + SD; h.week-1 = 8 ± 1.4). 
All participants were free from respiratory disease including asthma related conditions, 
cardiopulmonary disease, metabolic disease and musculoskeletal injury (TABLE 5.1). 
 
The participants completed all assessments at the same time of the day (within 1 h), separated 
by a minimum of 48 hours. They were instructed to sleep for at least 7 hours, drink at least 35 
mL/kg/day of water, refrain from consumption of alcohol for 24 hours prior to the visit and 












Table 5.1: Descriptive features of participants (n=13) 
 
Parameter            Mean ± St.Dev  
Age (years)                      18.1 ± 0.9     
Height (cm)                    178 ± 6.5  
Weight (kg)                      69.5 ± 8.3  
BMI (kg*m-2)                   22 ± 1.7    
VO2Max (mL/min/kg)     51.2 ± 3.4 
HRMax  (bpm)                           198 ± 4.0 
  
Training (h/week)              8 ± 1.4 
RpeMax  (u.a.)                     9 ± 1.0 
 
 
Abbreviations: BMI, body mass index; VO2Max, maximal oxygen uptake; 
HRmax, maximal heart rate; RPEmax, maximal rating of perceived exertion. 
* Training data are presented for 13 male participants. 
Data are presented as mean and standard deviation (Mean ± SD) 
 
 
5.2.2 Experimental Protocol 
Participants visited the respective testing facilities on three separate occasions, the first of 
which was a familiarization session. The final two visits were completed in a single blind 
random order and separated by two days. On each of these separate occasions players were 
required to complete three maximal “30-m” sprints followed by the Yo-Yo IRT and followed 








Fifteen minutes prior to the initiation of the first three 30 m sprints players inhaled one of the 
following treatments, via a pocket chamber:  
Treatment 1: 16 inhalations of placebo (containing water vapor) (PLA) 
Treatment 2: 16 inhalations of 100µg salbutamol (Ventolin Evohaler- GlaxoSmithKline, UK) 
(SAL) 
 
The order of PLA and SAL was randomized and counterbalanced by an order generated by 
online software (randomization.com).  
 
5.2.3 Sprint Test 
Before the assessments all participants completed the 11+ warm-up (Bizzini and Dvorak 2015) 
concluding with standardised mobility and flexibility exercises. After the warm up football 
players completed three 30 m maximal sprint with 60 s passive recovery time between each 
sprint (Taskin, 2008). Five minutes following the end of the Yo-Yo IRT, participants 
completed a further three 30 m sprints with a 60 s active recovery between each one.  
Consistent verbal encouragement was given to the players during each sprint. Players were 
encouraged to complete the sprints as fast as they could.  In order to record the time to cover 
the distance, a system of light gates (Brower Timing, Fairlee, Vermont, USA) were utilised. 
Heart rate (HR) was recorded throughout the sprints with the heart rate monitor (Polar m400 
HR, Polar Oy Finland); peak HR being noted for each condition during the intermittent football 
test. The mean time of the three efforts and the best sprint time were recorded. At the end of 
each set of three sprints a drop of blood (0.5 μL) was collected from the ear to obtain a capillary 
blood lactate sample at the end of the third sprint for the analysis of blood lactate concentration 




5.2.4 Yo-Yo test (Yo-Yo IRT) 
The Yo-Yo IRT intermittent recovery test consisted of repeated 2 x 20 m shuttle runs at a 
progressively increasing speed controlled by audio bleeps (Krustrup et al. 2003). Between each 
running bout the players had a 10 s active rest period, in a space of 5 m where they are 
encouraged to walk or jog. Following the completion of each stage players were asked to 
provide a rating of perceived exertion on a scale between 6 and 20 (Borg, 1982). When the 
players failed on two occasions to complete the 2 x 20 m within the required time the test was 
concluded and the distance covered was recorded. 
The reproducibility of the Yo-Yo IRT was tested and repeated within a week with a coefficient 
of variation (CV) around 4.9% (Krustrup et al., 2003). Heart rate was recorded during the entire 
fitness trial to monitor cardiovascular response induced by test.  
 
5.2.5 Motivation and Mood Questionnaires 
Before each visit participants completed questionnaires to measure motivation to train and 
mood via the Brunel Mood Scale and Matthews questionnaire (Matthews et al., 2001; Terry et 
al., 2003). The Brunel Mood Scale (BRUMS) was used to quantify current mood (“How do 
you feel right now?”) at baseline, before the 30 m sprint (pre-sprint) and post-sprint. The 
questionnaire included 24 items (e.g. “angry, uncertain, miserable, tired, nervous, energetic”) 
divided into six subscales: anger, confusion, depression, fatigue, tension, and vigour. Each item 
was answered on a five point scale (0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, 4 
= extremely), and each subscales, with the respective relevant items, was calculated with a raw 
score in the range of 0–16. For this experiment, only scores for the fatigue and vigour subscales 





Motivation related to Sprint and Yo-Yo test was measured using the success motivation and 
intrinsic motivation scales (Matthews et al., 2001). Each scale consisted of 7 items scored from 
0 to 4 points (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = very much, 4 = extremely). 
Motivation questionnaire was administered immediately before the 30 m sprint test. 
 
5.2.6 Statistical Analysis 
All data are presented as mean ± SD unless otherwise stated. Assumptions of statistical tests 
for normal distribution and sphericity of data were checked as appropriate and Greenhouse-
Geisser correction to the degrees of freedom was applied when violations to sphericity were 
found. Repeated measures ANOVAs were used to determine the effect of time (Sprint Pre vs 
Sprint Post) and condition (SAL vs. PLA) on peak power, mean power and highest speed 
reached during 30-m sprint. This same analysis was adopted to investigate vigor (pre-treatment 
vs. post-treatment), motivation (pre-treatment) and each physiological and perceptual 
parameter (Heart rate, Blood Lactate and RPE) at iso-time [end of warm-up (0 min) and each 
Yo-Yo IRT level completed]. 
 
Data from the Yo-Yo IRT1, heart rate and RPE were analysed from the start of the test (level 
5) up to the end of level 16; values recorded beyond this point were considered as the highest 
point reached at exhaustion, as football players began to drop out of the test from level 16 
onwards. Paired T-tests were used to compare motivation scales between the two conditions. 
Significant interactions were followed up with Bonferroni tests as appropriate. Significance 
was set at 0.05 (2-tailed) for all analyses and effect sizes for the repeated measures ANOVAs 
were calculated as partial eta squared (η²p), using the small = 0.02, medium = 0.13 and large = 
0.26 interpretation for effect size. All data analysis was conducted using the statistical packages 






All thirteen football players completed the Yo-Yo IRT test and the sprint assessment in both 
conditions, PLA and SAL. None of the participants reported unpleasant symptoms such as 
tachycardia, nausea, headache or sleep disturbance after inhaling 1600 µg salbutamol; none of 
the participants could correctly distinguish the difference between the PLA and SAL 
conditions. 
 
5.3.2 30 m Sprint Pre and Post Yo-Yo IRT  
30 m sprints conducted pre and post Yo-Yo IRT demonstrated no difference between PLA and 
SAL conditions for best sprint time pre (PLA 4.43 + 0.14 s; SAL 4.44 + 0.15 s);post (PLA 4.57 
+ 0.12 s; SAL 4.52 + 0.14 s); p=0.753 η²p = 0.008; FIGURE 5.1/A). Mean sprint time pre (PLA 
4.46 + 0.12 s; SAL 4.45 + 0.15 s);post (PLA 4.55 + 0.16 s; SAL 4.52 + 0.13 s); p=0.152, η²p 
= 0.163; FIGURE 5.1/B), highest speed reached pre (PLA 24.47 + 0.65 s; SAL 24.66 + 0.76 
s);post (PLA 24.56 + 0.34 s; SAL 24.81 + 0.49 s); p=0.859, η²p= 0.003; FIGURE 5.1/C). 
 
There is no interaction for best sprint time (p = 0.754; η²p = 0.008). Follow-up test revealed 
that best sprint time increased significantly from pre to post Yo-Yo IRT (p = 0.000; η²p = 
0.583) without difference in condition (p = 0.233; η²p = 0.193). 
 
There is no interaction for mean time (p = 0.152; η²p = 0.163). Follow-up test revealed that 
mean sprint increased significantly from pre to post Yo-Yo IRT (p = 0.000 η²p = 0.668) without 




There is no interaction for highest speed reached (p = 0.859 η²p = 0.003). Follow-up test 
revealed that highest speed reached decreased significantly from pre to post Yo-Yo IRT (p = 
0.000 η²p = 0.673) without difference in condition (p = 0.250 η²p = 0.108). 
 






                  
 
A 
 Data is presented by Mean and SD 
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                Data is presented by Mean and SD. 
 
Blood lactate following the pre yo-yo test sprints was not different between SAL and PLA 
(6.47 + 1.5 mM/L vs.7.0 + 1.2 mM/L; p=0.450, η²p = 0.021). The post Yo-Yo test sprint lactate 
values were not different between SAL and PLA conditions (9.3 + 2.4 mM/L vs.10.0 + 2.1 
mM/L; p=0.882, η²p = 0.007; FIGURE 5.2). 
 
FIGURE 5.2. “Lactate values collected after sprint pre Yo-Yo IRT and after sprint  















5.3.3 Yo-Yo Intermittent Recovery Test 
The distance covered during the Yo-Yo IRT did not differ between PLA (1660 ± 217 m) and 
SAL (1610 ± 229 m), p=0.153, η²p =0.224; (FIGURE 5.3). 
 














No significant changes were observed between PLA and SAL during the Yo-Yo IRT for HR 
(p=0.102; η²p =0.095) or RPE (p=0.195; η²p =0.134). HR was not different between PLA and 
SAL at any level of the Yo-Yo IRT (FIGURE 5.4). 
  
FIGURE 5.4 (A) “Heart rate response at the end of each Yo-Yo IRT level completed by all  





       
 




RPE was not different between PLA and SAL at any level of the Yo-Yo (FIGURE 5.4/B). 
 
 FIGURE 5.4 (B) “RPE response at the end of each Yo-Yo IRT level completed by PLA and SAL” 
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                Data is presented by Mean and SD 
 
5.3.4 Mood and Motivation Questionnaire 
The mood questionnaire revealed a significant decrease in vigour over time in both conditions 
(PLA pre 5.7 ± 0.6 UA, PLA post 3.6 ± 0.4 UA; SAL pre 5.4 ± 0.3 AU, SAL post 3.3 ± 0.5 
AU); (p = 0.01) with no main effect of condition (p = 0.49, η²p =0.01) or condition × time 
interaction (p = 0.29, η²p =0.17; TABLE 5.2). No differences were found for intrinsic 
motivation (p = 0.62, η²p =0.09) and motivation to succeed the task (PLA 5.1 ± 0.4 AU; SAL 










      
TABLE 5.2 “Vigour at pre and post-test and Motivation at pre- test in SAL and PLA” 
        SAL                                           PLA  
 Pre Post Pre Post 
BRUMS vigour (A.U.) 5.4 ± 0.3 3.3 ± 0.5 5.7 ± 0.6 3.6 ± 0.4 
Motivation (A.U.) 5.3 ± 0.5  5.1 ± 0.4      
 
Abbreviations: A.U. = arbitrary units; SAL = salbutamol; PLA = placebo;  





My study suggests that non-asthmatic football players who inhale 1600 µg of salbutamol do 
not experience improvements in 30 m sprint performance pre or post the Yo-Yo IRT test. 
Furthermore, Yo-Yo IRT performance, HR, lactate or RPE are not altered as a result of prior 
inhalation of 1600 µg of salbutamol. 
My results are similar to previous findings from my research group (Dickinson et al., 2015), 
where we did not observe any significant change in repeated sprints following a running 
protocol that simulated one half of a football match. The available data from previous 
investigations has been analysed in a systematic review and meta-analysis (Pluim et al., 2011), 
in which the authors concluded that endurance performance was not influenced by supra-
therapeutic doses of inhaled salbutamol (up to 800 µg). Additionally, the inhalation of β2-
agonists may blunt the enhancing effects induced by high intensity interval training on 




levels of β2-agonists as showed by several studies (Hostrup et al., 2018; Hostrup et al., 2014; 
Sanchez et al., 2012; Dickinson et al., 2014; Molphy et al., 2018).  
Furthermore, high intensity training (HIT) seems to blunt hypertrophy and changes in 
expression of sarcoplasmic reticulum Ca2+ ATPase isoforms (Hostrup et al., 2018). This 
mechanism remains to be interpreted but may be related to the fact that endurance training 
impedes with the growth-promoting signaling (Coffey & Hawley, 2017) induced upon β2-
adrenergic prompt (Koopman et al., 2010). 
The improvements seen in other studies with regard to sprint and power performance could be 
due to drug ability to stimulate a receptor rather than the amount of drug administered (Baker, 
2010). In regard to this, inhaled terbutaline may lead to same systemic concentration of doses 
administered orally with less side effects and prolonged drug persistence (Elers et al., 2012).  
 
Therefore, the absence of ergogenic action found in this study could be a summation of factors: 
the type of drug and the dosage used in our studies compared to other studies. While acute 
doses of inhaled salbutamol up to 1600 µg seem not to enhance 30-m sprint and Yo-Yo IRT 
performance, 15 mg of inhaled terbutaline increases 30-s sprint peak and mean power by 3% 
in recreational athletes (Hostrup et al., 2014). High doses of inhaled terbutaline (15 mg) have 
also been shown to improve 10 s cycling sprint performance in moderately trained cyclists with 
mean (8.3% ± 1.1%) and peak (7.8% ± 2.5%) power greater with terbutaline than with placebo 
(Kalsen et al., 2016). This suggests that supra-therapeutic doses of some inhaled short acting 
β2-agonists (e.g. 15 mg of inhaled terbutaline) lead to significantly greater systemic availability 
and therefore greater potential for ergogenic effects. However, adverse analytical finding 





Blood lactate is an indirect marker of muscle glycolysis; in our study I did not find a difference 
between PLA and SAL conditions. It has previously been reported that 800 µg dose of inhaled 
salbutamol can lead to detectable systemic concentrations of 10.95 ng/mL in healthy subjects 
(Elers et al., 2012; Elers et al., 2012a). Notwithstanding, in my study I was not able to direct 
measure the concentration of salbutamol in the blood or in urine as I did not have the resources 
available during the study. I can therefore not assume that a dose of 1600 µg inhaled salbutamol 
was a sufficient dose to lead to high levels of salbutamol in the systemic circulation.  
In my study I advised participants how to use inhaler and observed them using the inhaler but 
I did not train. Future studies may also benefit from thoroughly train inhaler technique with 
their participants to improve the delivery of salbutamol into the lower airways. 
During this study I did not have the resources available to collect urine samples from the 
footballers to evaluate urinary levels of salbutamol, this would have allowed us to examine any 
inter-subject variation that could have brought urinary levels above 1000 ng.ml-1 threshold for 
an AAF, cut-off limit allowed by WADA (WADA, 2019).  
However, some of my group previous findings (Dickinson et al., 2015) suggest the acute 
inhalation of supra-maximal doses of salbutamol (up to 1600 µg) along-side acute loss of body 
mass of up to 5% can lead to individuals presenting with a urinary salbutamol concentration 
above 1200 ng.ml-1. Haase et al., (2016) confirmed that dehydration can significantly affect the 
concentration of salbutamol in urine samples. Based upon Dickinson et al., (2015) and Haase 
et al., (2016) results, WADA now has adjusted its methods to analyse the concentration of 
salbutamol with dehydration state of the athletes (WADA, 2019). 
 
The trained status of the athlete may impact on the availability β2-adrenoceptor activity. It 
could be speculated that β2-adrenoceptors content might be lower in athletes being translated 




performance (Van Baak et al., 2004). In addition, it was observed that muscle mass was a 
confounder of the response to salbutamol administration because the more trained the 
participants were the lower the response (Hostrup et al., 2018). My participants were trained 
amateur athletes, and I may have seen different result if I had recruited less well training 
recreational football players.  
 
5.4.1 Conclusion 
This study demonstrates inhalation of 1600 µg salbutamol does not improve 30 m sprint 
performance in trained amateur football players. Furthermore, my findings suggest that acute 
inhalation of 1600 µg salbutamol will not lead to improvements in Yo-Yo IRT performance in 
football players. Although 1600 µg of inhaled salbutamol is greater than the current permitted 
dose (800 µg) by WADA regulations (WADA, 2019), my study suggests footballers using 
inhaled salbutamol for asthma therapy within the doses permitted WADA regulations will not 


















Chapter 6.   Acute Administration of 
Salmeterol Improves Sprint 

















Several studies suggest no ergogenic action is provoked by the inhalation of short-acting β2-
agonists (SABA) in endurance performance (Pluim et al., 2011; Koch et al., 2015a; Dickinson 
et al., 2014). However, studies using long-acting β2-agonists (LABA) showed controversial 
results when time to exhaustion was investigated in athletes inhaling formoterol (Stewart et al., 
2002) and salmeterol (Carlsen et al., 1997) when compared to the placebo.   
When sprint performance was tested after the inhalation of high doses of LABA, several studies 
showed an ergogenic effect on performance (Kalsen et al., 2013; 2016). However, at low doses, 
LABA seems to not be effective to increase sprint performance (Stewart et al., 2002). Contrary 
to previous results, salmeterol inhaled before performing 30-s all-out sprint showed no changes 
in performance (McDowell et al., 1997). SABAs daily administration in concomitance with 
strength and endurance training did not show performance improvements (Dickinson et al., 
2014). Previous studies were performed mainly in a non-fatigued state. Dickinson et al., (2015), 
instead, investigated the effect of 1600 µg salbutamol inhalation on repeated sprints in fresh 
and fatigued conditions. The authors did not find any difference in the sprint performance 
probably due to the effect of the fatiguing protocol that negatively impacted the potential 
benefit of salbutamol on sprint and repeated sprint performance.  
The importance to test the effect of any ergogenic aids not only in fresh states but also in 
fatigued ones is prominent in elite sport. To cite some examples, cycling race is made of high-
power efforts occurring during the start, steep climbing and at the final part of the stage in 
preparation of the way for the final sprint. Thus, the capacity to deal with increased levels of 
fatigue accumulated during the race is an important aspect to be considered (Menaspà et al., 
2015). Due to lack of studies in the literature miming the condition experienced by cyclist at 




the effect of salmeterol administration during sprints performed before and after a “race 
simulation” incremental test with attention on muscle activity responses. The hypothesis of this 
study is that salmeterol administration could increase the power produced during the first 12-s 
sprint and limiting the effect of fatigue development occurring during variable cycling test and 
during the subsequent 12-s sprint. 
 
6.2 Methods  
6.2.1 Study Participants 
Sixteen male road cyclists (mean ± SD, age 25 ± 1.7 y, height 180 ± 6 cm, body mass 75.7 ± 
8.4 kg, VO2Max 64.6 ± 6.9 mL• kg-1 min-1, peak power output (PPO) 419 ± 38 W, > 5 training 
sessions per week, > 400 km per week, > 5 years of cycling experience) were recruited. Taking 
into account PPO and training history cyclists were classified as level 4 (De Pauw et al., 2013). 
Participants were free form medication and demonstrated the absence of asthma and exercise 
induced bronchoconstriction (EIB) through a negative eucapnic voluntary hyperventilation 
(EVH) challenge. The study procedures were approved by the local research ethics committees 
between the University of Kent (UK) and the university of Verona (IT) and follow the ethical 
principles for medical research involving human subjects set by the World Medical Association 
Declaration of Helsinki. Participants signed the informed consent and were provided with 
written instructions outlining the study`s procedures but were not informed of its aims.  
 
6.2.2 Experimental Protocol 
A single-blind, crossover, counterbalanced and randomised, using web-based computer 
program (www.randomization.com), design was used in which participants visited the 
laboratory on four separate occasions (EIB test, incremental cycling test and two visits with 




Before starting to warm-up participants inhaled 100 µg salmeterol (2 x 50 µg Serevant, 
Accuhaler, GSK, Uk) (SAL condition) or placebo (PLA) containing water vapor.  
 
6.2.3 Broncho-provocation Challenge 
First visit aimed to investigate the presence of EIB using forced expiratory volume per second 
(FEV1) measurement.   
 
6.2.4 VO2Max Test  
During the second visit participants completed an incremental cycling exercise test (2 min at 
50 W + 50W/ 2 min) until voluntary exhaustion or until pedal frequency fell below 60 
revolutions/min (RPM) for more than 5 s. This test was performed on an electromagnetically 
braked cycle ergometer (Excalibur Sport, Lode, Groningen, The Netherlands). PPO and 
maximal oxygen consumption (MetaLyzer 3B, Cortex Biophysik, Leipzig, Germany) were 
recorded.  
 
6.2.5 Sprint Familiarisation 
Five minutes after completion of the incremental test, the ergometer was switched to isokinetic 
mode constrained to 110 rpm and participants (after a short warm-up) performed a 12-s all-out 
sprint to familiarize with the one performed during visit 3 and 4. The instantaneous power 
generated during the sprints was corrected for changes in kinetic energy and averaged over 1-
s intervals, taking into account the work executed in accelerating the flywheel. 
 
6.2.6 “Non-fatigued” Sprint Test  
One hour following the inhalation, subject began to warm up performing five minutes free-




and 75% of the maximal perceived effort with 0.5 to 5 min of active recovery between each 
sprint in accordance to Coelho et al., (2015). Afterwards, they performed a 12-s all out maximal 
sprint (Pre). After the maximal sprint a drop of blood was collected from the right earlobe for 
the analysis (Lactate Pro LT-1710, Arkray, Shiga, Japan) of lactate and participants began an 
hour variable cycling trial (VCT) executed on individual power based on the previous 
incremental test.  
 
6.2.7 Variable Cycling Test 
Variable cycling trial power was structured to mimic a cycling race competition of similar 
duration as proposed by Menaspà and colleagues (2015). However, we modified the power to 
allow cyclist to match the cycling intensities according with their levels. Variable cycling test 
(VCT) was as follow:  20 minutes at 40% of personal PPO, 15 minutes at 45%, 15 minutes at 
55%, 5 minutes at 65%, 4 minutes at 75% and one minute (59th) performed at 95% of personal 
PPO.  At end of min 35th and 59th blood lactate was collected. Pedal frequency (freely chosen 
between 80 and 100 RPM), heart rate (Polar S610i, Polar Electro Oy, Kempele, Finland) and 
RPE (6-20 Borg`s scale) were measured at end of min 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 
55 and at completion of the VCT. 
 
6.2.8 “Fatigued” Sprint Test 
Immediately after completion of the VCT, bike was switched in isokinetic mode and 
participants were asked to produce an all-out maximal 12-s sprint (Post) simulating the final 
sprint of a cycling race. Verbal encouragements were given (in both Pre and Post sprints) from 
a researcher blind to testing conditions.  At completion of the sprint, blood lactate was 
collected.  Peak power and mean power were measured at the end of each sprint. Surface EMG 




position and orientation of the array were obtained following criteria described by Lenti et al., 
(2010). The root-mean squared (RMS) EMG values from the muscle were filtered analyzed 
according to Coelho et al., (2015). Peak RMS (highest RMS value during the sprint) and mean 
RMS (the average value over the whole sprint) were computed and used for the statistical 
analysis. A normalization procedure was adopted to compare experimental EMG results 
collected from different subjects or days within subjects allowing to access the relative level 
of activation of a given muscle by expressing the entire amplitude of the signal measured during 
the task as a percentage of a important reference EMG rate (Hsu et al, 2016).  
 
6.2.9 Motivation Questionnaire 
Motivation related to Sprint and Time-Trial test was measured using the success motivation 
and intrinsic motivation scales (Matthews et al., 2001). Each scale consisted of 7 items scored 
from 0 to 4 points (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = very much, 4 = extremely). 
Motivation questionnaire was administered immediately before the inhalation undergone by 
the subjects before the warm-up. 
 
6.2.10 Statistical Analysis 
All data are presented as mean ± SD unless otherwise stated. Assumptions of statistical tests 
for normal distribution and sphericity of data were checked as appropriate and Greenhouse-
Geisser correction to the degrees of freedom was applied when violations to sphericity were 
found.  Fully repeated 2 x 2 ANOVAs were used to determine the effect of time (Pre vs Post 
sprint) and condition (SAL vs. PLA) on peak power and mean power during cycling sprint. 
Similarly, assessment was completed for peak-RMS and mean-RMS. Fully repeated 2 X 13 
ANOVAs were used to determine effect of condition (SAL vs. PLA) on RPE, HR and RPM 




condition on blood lactate concentration at different time points. Paired T-tests were used to 
compare motivation scales between the two conditions. Significant interactions for ANOVA’s 
was followed up with Bonferroni tests as appropriate. If significant interactions were not found, 
most relevant main effects are reported. Significance was set at 0.05 (2-tailed) for all analyses. 
The effect sizes for the repeated measures ANOVAs were calculated as partial eta squared 
(η²p), using the small = 0.02, medium = 0.13 and large = 0.26 interpretation for effect size. All 
data analysis was conducted using the statistical packages for social science (SPSS version 21). 
 
6.3 Results  
6.3.1 Participants Characteristics 
All sixteen cyclists completed the sprint test and the time-trial assessment in both conditions, 
PLA and SAL. None of the participants reported unpleasant symptoms such as tachycardia, 
nausea, headache or sleep disturbance after inhaling 100 µg salmeterol; none of the participants 
could correctly distinguish the difference between the PLA and SAL conditions. 
 
6.3.2 Motivation questionnaire 
Motivation did not change between the two conditions in PLA (3.27 ± 0.25 A.U.) and SAL 
condition (3.41 ± 0.32 A.U.); (p = 0.425, η²p = 0.049). 
 
6.3.3 Sprint Power Analysis 
There was a significant time x condition interaction for peak power during the sprint cycling 
(p = 0.016, η²p = 0.424). Follow-up tests revealed that peak power decreased significantly 
overtime from Pre to Post Variable cycling trial in both conditions (FIGURE 6.1A); (p < 0.001, 
η²p = 0.709), however the decrease was significantly higher (p = 0.040, η²p = 0.330) in the 




(Pre = 990 ± 105 W– Post = 915 ± 135 W).  
Similarly, a significant interaction time x condition was found for mean power (FIGURE 
6.1B); (p = 0.010, η²p = 0.470). Decrease in mean power from Pre to Post Variable cycling 
trial was significant in both conditions (p < 0.001, η²p = 0.766). However, mean power was 
reduced significantly more (p = 0.047, η²p = 0.313) in in the PLA condition (Pre = 801 ± 72 
W – Post = 643 ± 92 W) compared to the SAL condition (Pre =795 ± 95 W – Post = 692 ± 76 
W);(FIGURE 6.1A; FIGURE 6.1B). 
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(#) Significant main effect of time (p < 0.05); (*) Significant condition X time interaction (p < 0.05); ($) 
and simple main effect of condition according to Holm-Bonferroni method.  
 
6.3.4 Sprint RMS Analysis 
No significant condition x time interaction was found for peak-RMS during the cycling sprint 
tests (p = 0.566, η²p = 0.021).  No significant main effect of condition was found (p = 0.090, 
η²p = 0.170) while a significant main effect of time was detected as peak-RMS decreased 
overtime (p = 0.015, η²p = 0.319). No significant condition x time interaction was found for 




of condition was found (p = 0.364, η²p = 0.83) while a significant main effect of time was 
detected as mean-RMS decreased overtime (p = 0.035, η²p = 0.372).  
 
6.3.5 Variable Cycling Trial Perceptual and Physiological Analysis 
There was a significant condition x time interaction for heart rate during the variable cycling 
trial (p = 0.004; η²p = 0.211); (FIGURE 6.2A); 
Follow-up tests revealed that heart rate increased significantly overtime during time trial in 
both conditions (p < 0.001, η²p = 0.929), however the increase was significantly higher in the 
salmeterol condition at min 1 (p = 0.041), 5 (p = 0.049), 10 (p = 0.043) 15 (p = 0.038) and 20 
(p = 0.026) compared to the control condition. No significant condition x time interaction was 
found for RPE during the variable cycling trial (FIGURE 6.2B); (p = 0.323, η²p = 0.069).  No 
significant main effect of condition was found (p = 0.802, η²p = 0.004) while a significant main 
effect of time was detected as RPE increased overtime (p < 0.001, η²p = 0.933; FIGURE 6.2).  
 
FIGURE 6.2 “Effect of treatment on physiological and psychological responses during Variable Cycling 










(#) Significant main effect of time (p < 0.05); (*) Significant condition X time interaction (p < 0.05) ($) 






No significant condition x time interaction was found for Blood Lactate during the sprints and 
the time trial tests (p = 0.48, η²p = 0.049). No significant main effect of condition was found 
(p = 0.54, η²p = 0.028) while a significant main effect of time was detected as blood lactate 
changed overtime (p < 0.001, η²p = 0.724; FIGURE 6.3). No significant interaction (p = 0.538; 
η²p = 0.048) or main effect of condition (p = 0.653; η²p = 0.022) or time (p = 0.712, η²p = 
0.038) was found for pedal frequency.  
 
 
FIGURE 6.3 “Effect of salmeterol on blood lactate after 12-s sprint and during  









   (*) Significant main effect of time (p < 0.05). Data presented as means ± SD. 
 













My data suggests an acute 100 µg dose of inhaled salmeterol off-sets fatigue by improving all 
out 12-s sprint performance after a one-hour variable cycling trial through changes in power 
output. Similar sprint improvements were obtained in Chapter 4 aimed to investigate the effect 
of chronic β2-agonists administration in conjunction with strength training programme on 
running performance in recreational athletes. The authors showed a significant reduction in 
time needed to cover 30-m running distance in the group undertaking LABAs formoterol and 
salmeterol when compared with placebo group.  
Inhaled β2-agonists seems to counteract fatigue development as power output recorded during 
the final sprint at post was significantly higher (PPO + 11.4 % and MPO + 6.8%) in salmeterol 
condition than in placebo condition. The only study aimed to evaluate the effect of salmeterol 
inhalation on sprint performance was conducted by McDowell (McDowell et al., 1997). 
According to the authors, after 42µg salmeterol administration participants did not record 
performance improvement during 30-s maximal sprint. Contrary to these results, my study 
showed a higher power output during a 12-s sprint post one-hour variable cycling trial under 
salmeterol condition. One explanation can be that the effect of salmeterol is more visible during 
fatigue states similarly to the results coming from animal studies where an augmented Ca2+ 
release from the SR was observed after continuous tetanic stimulation (Cairns & Dulhunty, 
1994). Alternatively, it could be explained by the doses used by McDowell (1997) that were 
lower compared to the current study (42 µg and 100 µg respectively).  
Moreover, the study designs are different as in the previous study after the inhalation 
participants were requested to perform 12-s sprint before and after one-hour variable cycling 
test, whereas McDowell (1997) only performed a 30-s sprint 3 hours after the inhalation of 42 




Both studies did not show any improvement of salmeterol inhalation in sprint performed in a 
rested condition. In contrast to McDowell et al., (1997), Kalsen et al., (2016) reported a positive 
effect in the power output when LABA formoterol was administered to recreational 
participants during 30-s cycle-ergometer sprint test. Although measured in fatigued state, our 
findings are similar to previous investigations that have demonstrated higher force or power 
production following acute and chronic supplementation of β2-agonists (Caruso et al., 1995; 
Martineau et al., 1992; Van Baak et al., 2000).  
It has been proposed that the administration of β2-agonist has the potential to stimulate the 
central nervous system function by increasing voluntary activation of the muscle (Martineau 
et al., 1992). However, my results seem not to support this hypothesis as no changes in sEMG 
parameters were found. Similarly, previous investigations did not show changes in sEMG 
parameters, corticospinal response and voluntary activation (Decorte et al., 2008, 2013; 
Hostrup et al., 2015; Laurent et al., 2018).  
 
Therefore, I suggest that the ergogenic effect of acute β2-agonist seems to be mediated by 
improvement of peripheral muscle function (Kalsen et al., 2014; Hostrup et al., 2015).  
Twitch interpolation technique could help to detect muscle fatigue combining maximal 
voluntary contraction (MVC) in addition to an electrical stimulus applied to the nerve in order 
to localise exercise and contractile fatigue.  
In support of the latter, shorter half relaxation time after salbutamol administration was 
observed by Crivelli et al., (2011); higher ATP, G-6-P and unchanged PCr after the sprint 
observed by Kalsen et al., (2016) suggests a smaller accumulation of Pi, AMP and free Mg2+ 
that is identified to decrease force by impairing cross-bridge function and by reducing release 




associated with increased rates of glycogenolysis and glycolysis that may contrast the 
development of fatigue through an accelerated rate of ATP resynthesis (Allen et al., 2008). 
 During the variable cycling trial, heart rate was significantly higher in SAL condition compared 
to placebo heart rate response collected in the early phase (min 1 to min 20) was slightly higher 
following the inhalation of salmeterol probably responsible of the increased resting heart rate. 
Unfortunately, we could not record heart rate at rest due to logistic problems, however I would 
have expected higher resting rate under β2-agonists (Onslev et al., 2017). Heart rate did not 
reveal significant differences between conditions at higher intensities (from 55% to 95% PPO). 
These changes are similar to findings collected during the early phase of 10 km time-trial 
performed in a previous study (Koch et al. 2015). This could be the result of an overstimulation 
in the adrenergic nervous system mediated by both β1 and β2-receptors (Brodde, 1991) or by 
greater systemic bioavailability. The increased heart rate response observed at low intensities 
could be explained as β2-adrenergic free fatty acids mobilisation from adipose tissue (Hoeks et 
al., 2003) and subsequence hormone-sensitive lipase activation in skeletal muscle (Jocken et 
al., 2008). Conversely, at higher intensities when carbohydrate oxidation is maximised I did 
not observed difference in heart rate and in blood lactate between conditions probably due to 
exercise-induced release of adrenaline and noradrenaline (Kalsen et al., 2016) thus acting as 
competitor for salmeterol that reduced the difference in energy expenditure between placebo 
and salmeterol.  
However, our findings are not in agreement with Carlsen et al., (1997) who reported similar 
heart rate response during running time to exhaustion in placebo, salbutamol (0.8 mg) and 
salmeterol (50 µg) conditions. Notably, a comparison between my results and Carlsen (1997) 
is difficult; firstly, the type of test proposed by Carlsen’s study was shorter than mine (four 
minutes vs one-hour) and secondly, the running intensity in Carlsen (1997) study was closer to 




the last part of the incremental test (from minute 35 to 59) was conducted at similar intensity 
(91% of HRMax).  
In the current study perception of effort (RPE) did not reveal differences in both conditions. 
Previous studies measured leg discomfort (RPEL) in 10-km cycling time trial and 5-km running 
time-trial with a significant enhanced RPEL in salbutamol condition during a time trial 
(Dickinson et al., 2014; Koch 2015). It could be expected that increased rating of (RPEL) might 
be ergolytic for the athletes due to elevations in serum creatine kinase levels observed with 
higher doses of salbutamol (Lisi, 1989); however, in neither study the increase in RPEL lead to 
a significant effect on athletic performance (Pluim et al., 2011). Blood lactate increased 
significantly after the 12-s sprint in both conditions. The observation of lactate variation seems 
to be caused by power output changes during the time-trial. These results are in line with studies 
presenting muscle lactate increment from the start of supra-maximal exercise after acute 
salbutamol intake (Collomp et al., 2005).  
 
Overall, salmeterol administration has an ergogenic effect expressed by a reduced power output 
loss in sprinting activity performed after a fatigue-induced cycling protocol. We suggest that 
the ergogenic effect of LABAs can be due to an improvement in peripheral muscle function. 
However, due to the impossibility to measure it, my conclusion is only supported by previous 










6.4.1 Technical consideration and study limitations 
In the previous section I speculated that the higher force production in SAL condition was 
mediated by an improvement in peripheral muscle function. A limitation of this experiment is 
that central activation and peripheral muscle function were not assessed; therefore, our 
conclusion is mainly based on previous investigations. As such, additional research involving 
established protocols are needed to quantify central activation and peripheral muscle function 
following SAL supplementation. Similarly, urine collection will need to establish the exact 
amount of drug able to reach the systemic circulation in order to create a dose-response 
relationship. According to this, the time waited between the inhalation and the beginning of 
warm-up represents a limitation of this study because did not allow us to be sure about the 
concentration of salmeterol present in the systemic concentration after the inhalation. 
 
6.4.2 Conclusion 
This study was the first to demonstrate that 100 µg salmeterol inhalation improves 12-s sprint 
performance after a fatiguing protocol. It could be speculated that β2-adrenoceptors content 
might be lower in athletes being translated in a more prominent β2-adrenoceptors stimulation 
that would bring to improved sprint performance (Van Baak et al., 2004). Therefore, anti-
doping stake-holders may wish to commission investigations into whether asthmatic athletes 
experience a similar ergogenic action from inhaled long-acting β2-agonists. Future research 
should explore the effect of long-term administration to detect any potential doping effect 
following daily β2-agonists administration. More interestingly, whether daily β2-agonists 
administration could enhance β2-adrenergic endogenous levels even through the inhalation of 
similar long-acting β2-agonists. Our results suggest that consideration should be given to closer 
























































This thesis demonstrates that both inhaled SABAs and LABAs do not induce an ergogenic 
action on aerobic performance in cycling and running. Conversely, there appears to be a 
significant improvement in sprint performance in a fatigue state following acute inhalation of 
salmeterol. Furthermore, 5-week inhalation of either 100 μg salmeterol or 12 μg formoterol 
improved 30-m maximal running sprint in athletes involved in a training program based on 
strength and power exercises.  
 
The general discussion will be structured according to the different performance parameters 
analysed within my studies, discussing the main mechanisms exerted by IBAs administration 




Daily administration of either inhaled salmeterol or formoterol did not enhance strength 
parameters measured in subjects training for power and resistance as reported in the Chapter 
4. Similarly, Dickinson et al., (2014) observed that long-term daily doses of 1600 μg inhaled 
salbutamol administration in parallel with a full body training program did not alter strength 
and power performance. My findings are also similar to studies investigating oral doses of 
salbutamol, which have reported improvements in sprint performance in the absence of 
changes in maximal voluntary contraction (Hostrup et al., 2016). These findings could result 
from the combination of various effects induced by the drug and reinforced by the cumulative 
effect provoked by the training. As a consequence of this training, increased excitation-
contraction process with consequent accelerated rate of relaxation is observed. Likewise, 
increased concentric and eccentric strength in leg muscles was reported after 9 weeks of oral 




and power assessments maybe because participants performed extra aerobic training in 
addition to the prescribed training program in the study. Hence, future studies should look to 
control exercise completed by participants outside of that prescribed within the study. 
 
There are a limited number of studies investigating LABAs administration and its influence on 
strength and power in athletes. From the few that have been conducted, increases in maximal 
voluntary contraction (MVC) have been observed following acute high (54 μg) doses of 
formoterol (Kalsen et al., 2016) but not low doses (12 μg; Stewart et al., 2002). However, these 
studies used athletes of different training status between high level athletes (Stewart et al., 
2002) and recreational athletes (Kalsen et al., 2016). This is relevant as athletes with greater 
training/fitness level appear to have lower number of β2-adrenoceptors compared to lesser 
trained individuals (Butler et al., 1982). Overall, it seems that high doses of formoterol are able 
to increase strength values in recreational athletes while lower doses are not able to induce 
similar effect to high level athletes. However, these previous studies recruited participants with 
varying degrees of fitness and they did not specifically individualised the dose of drug inhaled. 
The limitations of these studies make it difficult to establish which of these variables mostly 
effected the performance. 
 
In summary, strength values are not increased after 5-weeks daily administration of LABAs 
despite a significant change in sprint performance. However, due to the difficulty to monitor 
the amount of drug present in the body throughout the entire program a dose-response 
relationship has not been established. This would be helpful to obtain important information in 
terms of levels of β2-agonists present in the systemic concentrations after daily doses 
administration, besides the time needed before a peak of drug is reached in the body avoiding 




Sprint and Power 
 
The effect of β2-agonists inhalation on sprint and power performance has been tested in all the 
three studies presented in this thesis without bringing significant improvements when SABAs 
(Chapter 5) and LABAs (Chapter 4 and 6) were administered.  
 
Despite asking participants to inhale twice the WADA permitted dose of salbutamol (WADA 
2020), I was unable to replicate the improvements in sprint performance observed by Hostrup 
et al., (2016) after oral salbutamol administration. Inhaling up to 1600 μg salbutamol may not 
sufficiently increase the systemic concentration of salbutamol to a significant level. It appears 
for salbutamol to increase sprint performance a significant systemic concentration is required 
to initiate elevated Ca2+ release, accelerated rate of relaxation (Crivelli et al., 2011) and elevate 
rates of glycogenolysis and glycolysis. However, since I did not measure the exact amount of 
β2-agonists present in the systemic concentration, I can only limit my observation on 
performance results that were unchanged when compared to placebo. The findings in my thesis 
fully agree with the results raised in literature where inhaled salbutamol does not induce 
ergogenic effects due to a weaker stimulation of β2-adrenoceptors when compared to oral 
administration (Elers et al., 2012). 
 
Similarly to inhaled salbutamol, I did not observe different peak and mean power during the 
12-s sprint between acute salmeterol and placebo condition. This could be affected by 
salmeterol onset of action that occurs twenty minutes following the inhalation with maximum 
improvement happening within three hours. However, I did not measure the amount of 
salmeterol present in the body when subjects began to warm-up and at the beginning of the 




the beginning of the warm-up (one hour) was possibly not long enough to induce significant 
drug concentration in the systemic circulation. This is an important point that should be 
investigated in the future to establish a dose-effect relationship through urine collection 
necessary to obtain the actual amount of drug concentration present in the body at the beginning 
of the warm-up. In addition to this, I have to consider that the type of warm-up developed in 
my study could have influenced the systemic concentration of LABAs. The criteria behind the 
decision of a warm-up made of repeated sprints is based on world-tour cyclists’ warm-up 
routine characterised by short-duration high-intensity intervals (Stickland et al., 2012); this 
warm-up strategy might reduce muscle glycogen and PCr storage through the stimulation of 
both the anaerobic lactic and alactacid system with partial energy depletion (Gastin, 2001).  
 
From blood lactate values collected after the sprints in Chapter 5 & Chapter 6, experimental 
conditions did not differ from placebo and this could be interpreted by insufficient doses 
administered in order to elicit adrenergic response; notwithstanding, the higher heart rate 
recorded during the first thirty minutes of the variable cycling trial in salmeterol condition 
could be the effect of a raise in the adrenergic system induced by long-acting β2-agonists 
administration. 
 
Conversely to acute IBA doses, after 5 weeks daily inhalation of either salmeterol or formoterol 
as reported in Chapter 4 a sprint improvement was observed under these conditions. This is a 
novel finding in this research area that suggests the ergogenic action of long-acting when 
administered in concomitance with strength and power training that could increase 





The improvement in sprint performance following 5-weeks salmeterol or formoterol could 
have been the result of several proposed mechanisms including: transition from slow to fast 
twitch fires increasing contractile properties of muscle (Caruso et al., 1995), central nervous 
systems alteration leading to improved motor unit synchronisation (Milner-Brown et al., 1975), 
or from an improved synergy between agonists and antagonist muscles during whole body 
training (Howard et al., 2018). According to Hostrup et al., (2015), the accelerated relaxation 
in excitation-contraction mechanism mediated by augmented Ca2+ handling function and larger 
ion shift of K+ and Na+, could be the primary cause of the increased sprint recorded in my 
study. Furthermore, the higher content of Na+/K+_ATPase collected after IBAs would 
counteract K+ loss and facilitating force development (Clausen, 2003).  
Future research may look to investigate each of these proposed mechanisms to fully explain 
the observations from my thesis. 
 
Overall, the improvement in sprint performance observed in Chapter 4 could be the result of  a 
better synergy between muscles and an increased neurological adaptation similar to what 
reported after chronic salbutamol administration (Martineau et al., 1992); in fact, the change in 
sprint performance but not in strength and lean body mass could be driven by central nervous 
system observed to be involved especially during the beginning of resistance training (Kramer 
et al., 1996). However, in my study I could not explain whether these results come from muscle 
fibres composition or from the central nervous system due to limited resources; in future studies 
I recommend to collect muscle biopsies in order to analyse whether change in muscle fibres 
could be provoked also by the administration of LABAs and resistance training.  
 
In conclusion, after acute SABAs administration no change in sprint and power performance 




body (Hostrup et al., 2018). Similarly, after acute LABAs administration, no change in sprint 




Five weeks of daily administration of inhaled salmeterol (100 μg) and formoterol (12 μg) daily 
administration did not to reduce body fat composition as when recorded by skinfolds 
measurements. These findings are in contrast to previous investigations utilising oral 
administration, where significant hypertrophic changes were recorded after oral salbutamol 
(Martineau et al., 1992; Le Panse et al., 2005; Le Panse et al., 2006) and reduced fat mass was 
detected after oral formoterol administration (Lee et al., 2015).  
 
Due to the lack of studies to compare inhaled and oral forms of LABAs, I do not know whether 
the absence of anabolic effect observed in my study is due to the weak dose inhaled or by the 
concurrent effect of the resistance program. Importantly, the use of skinfolds to assess body 
composition has an increased potential for error when compare with more sophisticated tools 
such as dual-energy X- ray absorptiometry (DEXA) (Pineau & Frey, 2016).  
 
When terbutaline was administered by inhalation, in concomitance with 4-week resistance 
training, a change in lean mass (+1.03 kg) was observed (Jessen et al., 2018). Notably, this 
effect seems even bigger after oral administration (+1.95 kg) in trained men (Hostrup et al., 
2015). I think that the difference between my study and the outcomes coming from the above 
studies (Jessen et al., 2018; Hostrup et al., 2015) is due by different pharmacodynamics and 
bioequivalence possessed by terbutaline that seems to have higher potency, efficacy, 




lipolytic terbutaline feature could be manifested by elevated β2-adrenoceptor affinities capable 




Sprint activity performed after Yo-Yo IRT (Chapter 5) did not differ with or without prior 
inhalation of salbutamol, however acute doses of salmeterol did improve sprint performance 
following a Variable cycling trial (Chapter 6). The sprint performed at the end of aerobic trials 
is mainly ascribable to muscle fatigue condition experienced by subjects before performing 
maximal 30-m running sprint and 12-s cycling sprint. With regard to this, it seems that only 
LABAs administration has an ergogenic action when muscles are in a relatively fatigued state, 
as reported by a decrement in power output compared to the cycling 12-s sprint performed 
under placebo condition and sprint performed in “non-fatigue” condition. 
The results from Chapter 5 seem to testify that inhaled SABAs (1600 μg salbutamol) do not 
increase power output during sprint performance, this may be due to reduced K+ levels as a 
consequence of high-intensity intermittent activity performed before. Similarly, high-dose 
inhaled terbutaline did not show increased MVC recording a significant lower peak twitch 
force after exhaustive exercise compared to placebo (Hostrup et al., 2014). Interestingly, the 
higher decrease in peak twitch force measured in terbutaline matched with a slower half-
relaxation time collected only during the second sprint suggesting the impact of this drug in 
“non-fatigued” condition, possibly ascribable to enhanced SR Ca2+ and K+ levels after the 
inhalation but not when exercise is prolonged with increased levels of fatigue. 
 
Similarly, the mechanisms behind the increased 12-s sprint showed in Chapter 6 have not been 




conditions, thus I would not attribute the higher power output collected in salmeterol condition 
to enhanced glycolytic metabolism. I think that the greater power output recorded during 12-s 
sprint by salmeterol could be determined by a small reduction of ATP content and by increased 
release of Ca2+ from sarcoplasmic reticulum compared to placebo (Kalsen et al., 2016). An 
increase in contractile force compared with placebo was probably responsible of the lower 
sprint reduction registered in salmeterol condition after the Variable cycling trial. However, 
since I could not collect further data, my considerations are mainly based on previous studies 
detecting larger Ca2+ release and faster rate of force relaxation after β2-agonists administration 
(Cairns & Dulhunty, 1994). Overall, the lower reduction of power output observed in 
salmeterol compared to placebo would be the result of muscle fatigue resilience effect of long-
acting β2-agonists in maintaining high levels of strength for prolonged period of time (Cairns 
& Dulhunty, 1994). However, it was not possible to confirm this mechanism within my study 
and future studies should investigate whether this is the case. 
 
My thesis brings important novel findings in terms of reduced loss of power output following 
100 μg salmeterol during 12-s sprint. Previous research may explain these findings by 
suggesting an increased rate of glycogenolysis and glycolysis along with great phosphorylation 
of CaMKII Thr and FXYD1 (Kalsen et al., 2016). The rationale behind the improvement 
observed in my study could be found in an acceleration of the accumulation of G-6-P with 
consequent counteraction in the reduction of ATP content in addition to reduced Pi 
accumulation, free Mg2+ and AMP with significant effects on fatigue development also 
showed  by an increment in Na+/K+_ATPase. In future studies I would seek to confirm these 
mechanisms occur in 12-s sprint in “fatigue state”. Conversely, the results obtained in Chapter 




related to a deprivation of Ca2+ release and re-uptake within the skeletal muscles and reduced 






The dose of salbutamol inhaled in Chapter 5 was the same used by Dickinson et al., (2015) that 
collected concentration of drug below the WADA urinary threshold without noticing 
significant improvement in performance.  I expect that a similar amount of drug was reached 
by my participants despite I could not measure urine values. Heart rate did not significantly 
increase compared to placebo conditions throughout the Yo-Yo IRT test, which suggests that 
supra-maximal doses of SABAs (1600 μg salbutamol) did not increase systemic β2-adrenergic 
levels significantly. This finding has also been reported by previous studies (Koch et al., 2015). 
Heart rate values were not different during the early phases of the Variable cycling trial while 
these were significantly higher after salmeterol inhalation. Contrary to what observed in 
Chapter 5, if no changes in heart rate were recorded, a possible higher adrenergic nervous 
system stimulation seems to occur with salmeterol compared to placebo. Notably, IBAs seem 
to stimulate β2-receptors present in skeletal muscle with consequent increased muscle 
metabolism activation (Carlsen et al., 1997). 
 
A limitation of this study is represented by the Variable cycling trial, as it was not performed 
until physical exhaustion, thus it was difficult to establish whether aerobic performance could 
have been augmented after LABAs administration. According to this, the choice to perform a 
time to exhaustion test could be suggested in order to assess the effect of LABAs in fatigue 
when the anaerobic metabolism is largely stressed with lactate production coming from 




few studies present in literature showing how SABAs do not enhance aerobic trials increasing 
heart rate as the results of an increased adrenergic activity (Koch et al., 2015a; 2015b). 
 
Due to similar RPE values in the two conditions and to the high correlation between RPE and 
the physiological response to exercise (Pereira et al., 2011) I would not expect a longer time to 
exhaustion following LABAs administration.  Notably, this supposition is based on the results 
I collected in my studies and it is also reinforced by few studies using RPE as measure of 
perceived leg fatigue (Koch et al., 2015a; 2015b). Despite Dickinson et al., (2014) reported 
greater RPE values in salbutamol condition during the first part of 5-km running time trial, no 
change in performance was recorded. Therefore, RPE maybe more of a surrogate for overall 
performance measurement rather than a measure to assess peripheral discomfort as described 
by Borg (1982). Thereafter, increased perception of effort reported in the above studies did not 
represent overall perception of effort but a measure of peripheral discomfort that is likely 
related to muscle cramping feeling when SABAs are administered (Lisi, 1989). With regard to 
this, RPE values collected during the aerobic exercise performed in this thesis seem to describe 
partially the results present in literature where the administration of β2-agonists does not 
improve aerobic performance even at supra-maximal regime.  
 
In summary, this thesis shows how SABAs administration do not increase the distance covered 
in the Yo-Yo IRT; these findings are reinforced by unchanged values of heart rate and 
perception of effort reported in Chapter 5. Conversely, the higher heart rate collected in Chapter 
6 during the early stages of the Variable cycling trial in salmeterol condition could be 
associated to a significant adrenergic activity incremented by the drug. The aim of Chapter 6 
was not to directly assess aerobic performance, I propose future studies to measure aerobic 




standardisation would ensure similar levels of β2-agonists in the body following the inhalation, 




Despite a familiarising participant to good inhaler technique and using a spacer device when 
possible, it was not feasible to assess what proportion of the inhaled dose was delivered into 
the lungs and how much was deposited on the upper airway. This could be partially due to the 
fact that familiarisation process was undergone for a short period of time (< 5 days) and 
supported by the data present in literature that recognise a small percentage of subjects with 
optimal inhaler technique (Giraud et al., 2016). A rigorous familiarisation over at minimum of 
4-weeks may improve the inhalation technique thus increasing the amount of IBAs reaching 
the small lower airways. 
 
All the studies present in this thesis and others in literature (Kalsen et al., 2016; Jessen et al., 
2018; Hostrup et al., 2018; Dickinson et al., 2014) administered drug to participants regardless 
a body-weight adjustment making difficult to establish a dose-response relationship provoked 
by SABAs and LABAs administration. Therefore, heavier participants may have effectively 
received a relatively small dose of β2-agonists when compared to lighter subjects. Prescribing 
appropriate doses of drugs requiring weight-based dosing is still challenging due to poor 
awareness and adherence; however, in population pharmacokinetic modelling, covariate 
models are built to describe between-subject variability in pharmacokinetic parameters (e.g. 
anabolic effects, clearance, onset of action) based on patient information (e.g. weight; Mould 




pharmacokinetic models is the body weight of the patient that need to describe its relationship 
with pharmacokinetic parameters (Anderson et al., 2006). 
Using doses of inhaled asthma therapy in relation to body mass will help to better understand 
the levels of β2-agonists present in systemic concentrations and the evaluation of drug-response 
relationship. The above limitation is likely to persist in studies conducted in the foreseeable 
future, as asthma inhalers are produced delivering metered doses making it impossible to 
individualise the dose directly in relation to body mass. 
 
A third limitation to report in this thesis is represented by the time waited between the 
inhalation of salmeterol and the beginning of Chapter 6 warm-up; this could have limited the 
amount of LABAs present in the systemic circulation explaining the absence of effect showed 
in “12-s non-fatigue” sprint. The time of absorption of salmeterol in the lungs is about 5 
minutes and within 15 minutes it is distributed in the bronchiolar regions (Backstrom et al., 
2018) reaching a body peak concentration in 45 to 90 minutes after the inhalation (Cazzola et 
al., 2002). Importantly, the drug concentration in the body seems to be affected by physical 
exercise with a reduced absorption rate from the GI tract at high exercise intensity (Kirjavainen 
et al., 2018). After the inhalation of terbutaline, blood levels and concentration curve (AUC) 
during exercise were greater than at rest with higher drug bioavailability (Schmekel et al., 
1992). According to this, drug availability in the body could have been increased at the very 
beginning of the warm-up through an increment of muscle blood flow in muscle; however, the 
duration and intensity of the type of warm-up performed in Chapter 6 could have reduced the 
amount of drug present in the body without benefit the sprint activity recorded. According to 
this, I cannot exclude that with a different type of warm up a higher amount of drug would 





Notably, when looking at endurance results collected in Chapter 5, internal variability of Yo-
Yo IRT test should be taken in account in behalf of day-to-day athletes’ variability especially 
during pre-season period where footballers fitness levels change more rapidly compared to “in-
season” (Castagna et al., 2013). Likewise, I tried to maintain the same application 
circumstances in test-retest (e.g. day-time, recovery, fatigue, quality of sleep) in order to reduce 
bias and limiting the observation on the effect of salbutamol administration. Furthermore, 
motivation and mood were measured in order to maintain the same engagement between 
sessions. 
 
A limitation present in Chapter 4 was the difficulty to control external factors (e.g. training 
performed outside the gym) that should have been maintained identical among all the three 
groups to limit the observation to the effect provoked by LABAs administration. In addition to 
the randomisation method I adopted to randomly assigned drug treatment to the experimental 
groups, I could have controlled external variables matching the different groups of confounding 
variables (e.g. type of sport performed, volume and intensity of the training) in order to be 
distributed equally amongst the group (Street, 1995). Unfortunately, due to the small number 
of subjects, I found difficult to extend matching within all the groups tested. Future studies 
may consider limiting activities outside the prescribed training. 
 
The above point links with a further limitation with regards the fitness and activity level of the 
participants. This is not just a limitation to my work but also most other studies on SABA and 
LABA. One potential solution is to recruit sedentary individuals as this may enable 
investigation into the ergogenic action of IBAs in the absence of physical activity. However, 
this strategy would not be directly applicable to athletes, partly due to reported differences in 




research investigating IBAs in relation to anti-doping regulations would recruit elite athletes to 
make the findings directly applicable. However, it is highly unlikely a true randomised control 
trial would be possible within an elite athlete population, as it would increase the risk of athletes 
contravening anti-doping rules. Furthermore, researchers are likely to find an inability to 
disrupt athletes training and competition schedule.  
 
Practical application of thesis finding 
 
This thesis suggests that WADA guidelines are appropriate for SABAs (salbutamol) but it 
should reconsider its position in regard of LABAs (SAL and FOR) guidelines to closer 
monitoring of athletes’ use of long-acting forms in and out of competition. Before changes are 
made to the WADA antidoping code, further investigations need to be done to better 
understand the ergogenic mechanisms behind the improvement showed in sprint performance. 
The next mandatory step is to include professional males and female athletes in similar studies 
so as to observe whether β2-agonists administration produce similar responses to what observed 
in recreational subjects. 
 
Based on my findings anti-doping stakeholders may wish to commission investigations into 
whether highly trained athletes experience similar ergogenic action from inhaled FOR or SAL 
as demonstrated in this thesis. These studies should be conducted before changes to the WADA 
Prohibited List are recommended. In particular, WADA may focus on the impact of chronic 
IBAs administration on strength and power activities when athletes are in fatigue states. 
Measuring change in maximal voluntary contraction between the beginning and the end of 
repeated sprint sessions would implement the observations coming from my thesis; this would 




after salmeterol administration. Moreover, future studies should look at the effect of acute 
LABAs administration in “non-fatigue” sprint ability controlling those aspects such as warm-
up that could have influenced the data collected at the beginning of the session. 
 
Further investigations on daily LABAs administration should be developed during consecutive 
days of cycling trial with the aim to simulate the effect of fatigue experienced by cyclists during 
congested period of races. This will mimic the stress accumulated by athletes involved in multi-
days competition, such as Grand Tour events, where the need to high quality recovery between 




In conclusion this thesis shows that supra-therapeutic SABAs doses do not increase sprint 
performance and aerobic performance in footballers confirming the results already present in 
the literature. The novel finding of this thesis is represented by the ergogenic effect provoked 
by the inhalation of long-acting β2-agonists (FOR and SAL) in both acute and chronic 
administration. More specifically, this thesis shows that the ergogenic feature possesses by 
salmeterol is significantly relevant on 12-s cycling sprint performed in a state of fatigue. 
However, the absence of effect showed in “non-fatigue” condition could be the results of 
methodological limitations that should be addressed in future studies.  
The combination of strength and power training and daily inhalation of LABAs showed a 
significant improvement in 30-m sprint performance in FOR and SAL groups but not in PLA. 
Future studies should look at peripheral changes through muscle biopsies and fibres analysis 
to detect any structural modifications provoked by daily β2-agonists administration in 
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